<SEC-DOCUMENT>0001811884-22-000012.txt : 20220812
<SEC-HEADER>0001811884-22-000012.hdr.sgml : 20220812
<ACCEPTANCE-DATETIME>20220812131400
ACCESSION NUMBER:		0001811884-22-000012
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		43
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220812
DATE AS OF CHANGE:		20220812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		221159135

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>utmd-20220630.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:dei='http://xbrl.sec.gov/dei/2022' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2020-01-21' xmlns:us-gaap='http://fasb.org/us-gaap/2022' xmlns:srt='http://fasb.org/srt/2022' xmlns:fil='http://www.utahmed.com/20220630' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='D220101_220630' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:CurrentFiscalYearEndDate' contextRef='D220101_220630' id='fact2'>--12-31</ix:nonNumeric>
<ix:nonNumeric name='dei:EntityCurrentReportingStatus' contextRef='D220101_220630' id='fact3'>Yes</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='D220101_220630' id='fact4'>false</ix:nonNumeric>
<ix:nonNumeric name='dei:DocumentFiscalYearFocus' contextRef='D220101_220630' id='fact5'>2022</ix:nonNumeric>
<ix:nonNumeric name='dei:DocumentFiscalPeriodFocus' contextRef='D220101_220630' id='fact6'>Q2</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utmd-20220630.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='D220101_220630'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='E22Q2'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E21Q2'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2021-06-30</i:instant>
</i:period>
</i:context>
<i:context id='I220811'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-08-11</i:instant>
</i:period>
</i:context>
<i:context id='E21'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='Y22Q2'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y21Q2'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2021-04-01</i:startDate>
<i:endDate>2021-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D210101_210630'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2021-01-01</i:startDate>
<i:endDate>2021-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='E20'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2020-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='Y22Q1'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q1_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q1_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q1_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q1_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='E22Q1'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q1_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q1_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q1_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q1_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='Y22Q2_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='E22Q2_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q2_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q2_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E22Q2_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E20_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E20_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E20_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E20_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-12-31</i:instant>
</i:period>
</i:context>
<i:context id='Y21Q1'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2021-01-01</i:startDate>
<i:endDate>2021-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y21Q1_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2021-01-01</i:startDate>
<i:endDate>2021-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y21Q1_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2021-01-01</i:startDate>
<i:endDate>2021-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y21Q1_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2021-01-01</i:startDate>
<i:endDate>2021-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y21Q1_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2021-01-01</i:startDate>
<i:endDate>2021-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='E21Q1'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2021-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E21Q1_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E21Q1_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E21Q1_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E21Q1_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-03-31</i:instant>
</i:period>
</i:context>
<i:context id='Y21Q2_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2021-04-01</i:startDate>
<i:endDate>2021-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y21Q2_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2021-04-01</i:startDate>
<i:endDate>2021-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y21Q2_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2021-04-01</i:startDate>
<i:endDate>2021-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y21Q2_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2021-04-01</i:startDate>
<i:endDate>2021-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='E21Q2_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E21Q2_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E21Q2_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E21Q2_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-06-30</i:instant>
</i:period>
</i:context>
<i:context id='D220101_220630_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-Obstetrics'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-Obstetrics_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-Obstetrics_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-Obstetrics'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-Neonatal'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-Neonatal_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-Neonatal_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-Neonatal'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q2_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-04-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-Obstetrics_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-Obstetrics_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-Neonatal_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-Neonatal_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='fil:DistributionRightsAcquisitionAxis'>fil:CoopersurgicalIncMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='D220630_DistributionRightsAcquisition-CoopersurgicalInc'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='fil:DistributionRightsAcquisitionAxis'>fil:CoopersurgicalIncMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-06-30</i:startDate>
<i:endDate>2022-06-30</i:endDate>
</i:period>
</i:context>
<i:unit id='Pure'>
<i:measure>xbrli:pure</i:measure>
</i:unit>
<i:unit id='USD'>
<i:measure>iso4217:USD</i:measure>
</i:unit>
<i:unit id='Shares'>
<i:measure>xbrli:shares</i:measure>
</i:unit>
<i:unit id='UsdPerShare'>
<i:divide>
<i:unitNumerator>
<i:measure>iso4217:USD</i:measure>
</i:unitNumerator>
<i:unitDenominator>
<i:measure>xbrli:shares</i:measure>
</i:unitDenominator>
</i:divide>
</i:unit>
</ix:resources>
</ix:header>
</div>
<div><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>UNITED STATES</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>SECURITIES AND EXCHANGE COMMISSION</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>Washington, D.C. &#160;20549</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><b>FORM </b><ix:nonNumeric name='dei:DocumentType' contextRef='D220101_220630' escape='true'>10-Q</ix:nonNumeric></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0'><span style='font-family:MS Gothic'><ix:nonNumeric name='dei:DocumentQuarterlyReport' contextRef='D220101_220630' format='ixt-sec:boolballotbox'>&#9746;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>For the quarterly period ended <ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='D220101_220630' format='ixt:datemonthdayyearen'> June 30, 2022</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>OR</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0'><span style='font-family:MS Gothic'><ix:nonNumeric name='dei:DocumentTransitionReport' contextRef='D220101_220630' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>For the transition period from  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Commission File No. <span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityFileNumber' contextRef='D220101_220630' escape='true'>001-12575</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='D220101_220630' escape='true'>UTAH MEDICAL PRODUCTS INC</ix:nonNumeric></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>(Exact name of Registrant as specified in its charter)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='D220101_220630' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='D220101_220630' escape='true'>87-0342734</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of incorporation or organization)</p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(I.R.S. Employer&#160;Identification No.)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='D220101_220630' escape='true'>7043 South 300 West</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='D220101_220630' escape='true'>Midvale</ix:nonNumeric>, <ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='D220101_220630' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric> &#160;<ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='D220101_220630' escape='true'>84047</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices) (Zip Code)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>(<ix:nonNumeric name='dei:CityAreaCode' contextRef='D220101_220630' escape='true'>801</ix:nonNumeric>) </span><ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='D220101_220630' escape='true'>566-1200</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Registrant&#8217;s telephone number, including area code)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0'>Securities registered pursuant to Section 12(b) of the Act:</p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Title of each class:</p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Trading Symbol:</p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Name of each exchange on which registered:</p>
</td></tr>
<tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:Security12bTitle' contextRef='D220101_220630' escape='true'>Common stock, $0.01 par value</ix:nonNumeric></p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:TradingSymbol' contextRef='D220101_220630' escape='true'>UTMD</ix:nonNumeric></p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:SecurityExchangeName' contextRef='D220101_220630' escape='true'>NASDAQ</ix:nonNumeric></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<span style='-sec-ix-hidden:fact3'>Yes</span>&#160;<span style='font-family:MS Gothic'>&#9746;</span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9744;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric name='dei:EntityInteractiveDataCurrent' contextRef='D220101_220630' escape='true'>Yes</ix:nonNumeric>&#160;<span style='font-family:MS Gothic'>&#9746;</span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9744;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Large accelerated filer&#160;<span style='font-family:MS Gothic'>&#9744;</span></p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Accelerated filer&#160;<span style='font-family:MS Gothic'>&#9744;</span></p>
</td></tr>
<tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'><ix:nonNumeric name='dei:EntityFilerCategory' contextRef='D220101_220630' format='ixt-sec:entityfilercategoryen'>Non-accelerated filer</ix:nonNumeric> <span style='font-family:MS Gothic'>&#9746;</span></p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Smaller reporting company <span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntitySmallBusiness' contextRef='D220101_220630' format='ixt-sec:boolballotbox'>&#9746;</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Emerging growth company <span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='D220101_220630' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style='font-family:MS Gothic'>&#9744;</span> &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;Yes&#160;<span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntityShellCompany' contextRef='D220101_220630' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9746;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock as of August 11, 2022: <ix:nonFraction name='dei:EntityCommonStockSharesOutstanding' contextRef='I220811' unitRef='Shares' decimals='INF' scale='0' format='ixt:numdotdecimal'>3,624,932</ix:nonFraction>.&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a1'></a><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>INDEX TO FORM 10-Q</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>PAGE</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a4' style='text-decoration:none'>PART I - FINANCIAL INFORMATION</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a4' style='text-decoration:none'>Item 1.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a4' style='text-decoration:none'>Financial Statements</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a5' style='text-decoration:none'>Consolidated Condensed Balance Sheets as of June 30, 2022 and December 31, 2021</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a6' style='text-decoration:none'>Consolidated Condensed Statements of Income for the three and six months ended June 30, 2022 and June 30, 2021</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a7' style='text-decoration:none'>Consolidated Condensed Statements of Cash Flows for the six months ended June 30, 2022 and June 30, 2021</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>3</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a8' style='text-decoration:none'>Consolidated Condensed Statements of Stockholders&#8217; Equity for the three and six months ended June 30, 2022 and June 30, 2021</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>4</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a9' style='text-decoration:none'>Notes to Consolidated Condensed Financial Statements</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>5</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a10' style='text-decoration:none'>Item 2.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a10' style='text-decoration:none'>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>7</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a11' style='text-decoration:none'>Item 3.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a11' style='text-decoration:none'>Quantitative and Qualitative Disclosures About Market Risk</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>17</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a12' style='text-decoration:none'>Item 4.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a12' style='text-decoration:none'>Controls and Procedures</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>17</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a13' style='text-decoration:none'>PART II &#8211;&#160;OTHER INFORMATION</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a14' style='text-decoration:none'>Item 1.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a14' style='text-decoration:none'>Legal Proceedings</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>18</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a15' style='text-decoration:none'>Item 1A.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a15' style='text-decoration:none'>Risk Factors</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>18</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a16' style='text-decoration:none'>Item 2.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a16' style='text-decoration:none'>Unregistered Sales of Equity Securities and Use of Proceeds</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>19</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a17' style='text-decoration:none'>Item 6.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a17' style='text-decoration:none'>Exhibits</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>20</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a18' style='text-decoration:none'>SIGNATURES</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>20</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a4'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>PART I - FINANCIAL INFORMATION</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><b>Item 1. Financial Statements</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a5'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:12.75pt'><td colspan='4' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='4' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED BALANCE SHEETS AS OF</span></p>
</td></tr>
<tr style='height:8.25pt'><td colspan='4' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>JUNE 30, 2022 AND DECEMBER 31, 2021</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='4' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands)</p>
</td></tr>
<tr style='height:21pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(unaudited)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(audited)</p>
</td></tr>
<tr style='height:19.5pt'><td valign='bottom' style='padding-right:5.75pt'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>JUNE 30, 2022</span></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>DECEMBER 31, 2021</span></p>
</td></tr>
<tr style='height:19.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><span style='border-bottom:1px solid #000000'>ASSETS</span></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Current assets:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Cash &amp; investments</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>66,224</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160;&#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>60,974</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts &amp; other receivables, net</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccountsReceivableNetCurrent' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,938</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccountsReceivableNetCurrent' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,132</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Inventories</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,338</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,596</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other current assets</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherAssetsCurrent' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>453</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherAssetsCurrent' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>456</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total current assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AssetsCurrent' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>78,953</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AssetsCurrent' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>73,158</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Property and equipment, net</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PropertyPlantAndEquipmentNet' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,171</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PropertyPlantAndEquipmentNet' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,618</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Operating lease &#8211;&#160;right-of-use assets, net</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAsset' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>420</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAsset' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>449</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Goodwill</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Goodwill' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,396</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Goodwill' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14,098</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other intangible assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsGross' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>52,560</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsGross' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>55,865</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other intangible assets - accumulated amortization</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>39,351</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>38,552</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other intangible assets, net</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IntangibleAssetsNetExcludingGoodwill' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,209</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IntangibleAssetsNetExcludingGoodwill' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>17,313</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total assets</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:Assets' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>116,149</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:Assets' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>115,636</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><span style='border-bottom:1px solid #000000'>LIABILITIES AND STOCKHOLDERS' EQUITY</span></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Current liabilities:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts payable</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:AccountsPayableCurrent' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>818</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:AccountsPayableCurrent' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>761</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accrued expenses</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccruedLiabilitiesCurrent' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,621</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccruedLiabilitiesCurrent' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,984</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total current liabilities</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:LiabilitiesCurrent' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,439</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:LiabilitiesCurrent' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,745</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Deferred tax liability &#8211; Femcare IIA</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,707</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,105</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Other long term liabilities</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherLiabilitiesNoncurrent' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,675</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherLiabilitiesNoncurrent' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,675</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Operating lease liability</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OperatingLeaseLiabilityNoncurrent' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>368</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseLiabilityNoncurrent' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>396</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Deferred income taxes</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredIncomeTaxLiabilitiesNet' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>489</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredIncomeTaxLiabilitiesNet' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>577</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total liabilities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Liabilities' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,678</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Liabilities' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,498</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Stockholders' equity:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Common stock - $<ix:nonFraction name='us-gaap:CommonStockParOrStatedValuePerShare' contextRef='E22Q2' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockParOrStatedValuePerShare' contextRef='E21' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name='us-gaap:CommonStockSharesAuthorized' contextRef='E22Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesAuthorized' contextRef='E21' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>50,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding - June 30, 2022, <ix:nonFraction name='us-gaap:CommonStockSharesIssued' contextRef='E22Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesOutstanding' contextRef='E22Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,625</ix:nonFraction></ix:nonFraction> shares and December 31, 2021, <ix:nonFraction name='us-gaap:CommonStockSharesIssued' contextRef='E21' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesOutstanding' contextRef='E21' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction></ix:nonFraction> shares</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CommonStockValue' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CommonStockValue' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accumulated other comprehensive loss</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1' contextRef='E22Q2' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,858</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1' contextRef='E21' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,054</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Additional paid-in capital</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdditionalPaidInCapitalCommonStock' contextRef='E22Q2' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdditionalPaidInCapitalCommonStock' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>841</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Retained earnings</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RetainedEarningsAccumulatedDeficit' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>119,293</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RetainedEarningsAccumulatedDeficit' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>115,314</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total stockholders' equity</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,471</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,138</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total liabilities and stockholders' equity</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:LiabilitiesAndStockholdersEquity' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>116,149</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:LiabilitiesAndStockholdersEquity' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>115,636</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>1</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a6'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:12.75pt'><td colspan='9' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND JUNE 30, 2021</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands, except per share amounts - unaudited)</p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Three Months Ended </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Six Months Ended </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>June 30, 2022</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>June 30, 2021</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>June 30, 2022</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>June 30, 2021</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000'></td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Sales, net</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,428</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,604</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>25,752</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>23,568</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cost of goods sold</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,277</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,819</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,069</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,836</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Gross profit</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,151</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,785</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>15,683</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14,732</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating expense</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Selling, general and administrative</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,959</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,892</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,846</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,821</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Research &amp; development</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>135</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>128</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>258</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>259</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total operating expenses</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,094</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,020</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,104</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,080</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Operating income</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,057</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,765</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,579</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,652</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other income</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>142</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>60</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>150</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>71</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Income before provision for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,199</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,825</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,729</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,723</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Provision for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,096</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,399</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,091</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,273</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net income</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,103</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,426</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,638</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,450</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per common share (basic)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y22Q2' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.13</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y21Q2' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.94</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D220101_220630' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.09</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D210101_210630' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.77</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per common share (diluted)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y22Q2' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.12</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y21Q2' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.94</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D220101_220630' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.09</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D210101_210630' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.76</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Shares outstanding - basic</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y22Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,643</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y21Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,646</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D220101_220630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,649</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D210101_210630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,645</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Shares outstanding - diluted</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y22Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,650</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y21Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D220101_220630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,658</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D210101_210630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,656</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other comprehensive income (loss):</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:23.25pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Foreign currency translation net of taxes of $<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y22Q2' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y21Q2' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='D220101_220630' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='D210101_210630' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'>0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in all periods</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q2' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,298</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>49</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D220101_220630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,804</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D210101_210630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5</ix:nonFraction>)</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total comprehensive income</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,805</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,475</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,834</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,445</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:38.9pt'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>2</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a7'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND JUNE 30, 2021</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands - unaudited)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Six Months Ended<br/>June 30,</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2022</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2021</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM OPERATING ACTIVITIES:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,638</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,450</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Adjustments to reconcile net income to net<br/> &#160;cash provided by operating activities</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Depreciation</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Depreciation' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>302</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Depreciation' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>325</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Amortization</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AmortizationOfIntangibleAssets' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,257</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AmortizationOfIntangibleAssets' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,335</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'><span style='font-family:Times New Roman'>Provision for (recovery of) losses on accounts receivable</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:ProvisionForDoubtfulAccounts' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>26</ix:nonFraction> </span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:ProvisionForDoubtfulAccounts' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8</ix:nonFraction> </span></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Amortization of Right-of-Use Assets</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>26</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'><span style='font-family:Times New Roman'>Deferred income taxes</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:DeferredIncomeTaxExpenseBenefit' contextRef='D220101_220630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>286</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:DeferredIncomeTaxExpenseBenefit' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>22</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Stock-based compensation expense</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ShareBasedCompensation' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>83</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ShareBasedCompensation' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>82</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Tax benefit attributable to exercise of stock options</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxExpenseFromStockOptionsExercised' contextRef='D220101_220630' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxExpenseFromStockOptionsExercised' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Changes in operating assets and liabilities:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts receivable and other receivables</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsReceivable' contextRef='D220101_220630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>102</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsReceivable' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>517</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Inventories</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInInventories' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>930</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInInventories' contextRef='D210101_210630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>75</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Prepaid expenses and other current assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>47</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts payable</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsPayable' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>64</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsPayable' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>399</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accrued expenses</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccruedLiabilities' contextRef='D220101_220630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>357</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccruedLiabilities' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>34</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total adjustments</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,240</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,775</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash provided by operating activities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:NetCashProvidedByUsedInOperatingActivities' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,878</ix:nonFraction> </span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:NetCashProvidedByUsedInOperatingActivities' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,225</ix:nonFraction> </span></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM INVESTING ACTIVITIES:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Capital expenditures for:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Property and equipment</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquirePropertyPlantAndEquipment' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>450</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquirePropertyPlantAndEquipment' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>222</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Intangible assets</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:PaymentsToAcquireIntangibleAssets' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:PaymentsToAcquireIntangibleAssets' contextRef='D210101_210630' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash used in investing activities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInInvestingActivities' contextRef='D220101_220630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>459</ix:nonFraction>) </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInInvestingActivities' contextRef='D210101_210630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>222</ix:nonFraction>) </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM FINANCING ACTIVITIES:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Proceeds from issuance of common stock - options</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProceedsFromIssuanceOfCommonStock' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>23</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProceedsFromIssuanceOfCommonStock' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>92</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Common stock purchased and retired</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsForRepurchaseOfCommonStock' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,495</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PaymentsForRepurchaseOfCommonStock' contextRef='D210101_210630' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Payment of dividends</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsOfDividends' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,060</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsOfDividends' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,077</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash used in financing activities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInFinancingActivities' contextRef='D220101_220630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,532</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInFinancingActivities' contextRef='D210101_210630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,985</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Effect of exchange rate changes on cash</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='D220101_220630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>637</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='D210101_210630' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>102</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net increase in cash and cash equivalents</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,250</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,916</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cash at beginning of period</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>60,974</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E20' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>51,590</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cash at end of period</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>66,224</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>59,506</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td colspan='2' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Cash paid during the period for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:IncomeTaxesPaid' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,467</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:IncomeTaxesPaid' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,279</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Cash paid during the period for interest</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InterestPaid' contextRef='D220101_220630' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InterestPaid' contextRef='D210101_210630' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>3</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a8'></a><p style='font:10pt CG Times;margin:0'></p>
<table style='border-collapse:collapse;width:100%'><tr style='height:12.75pt'><td colspan='12' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='12' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY FOR THE</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='12' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='12' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(In thousands - unaudited)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Accumulated</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Additional</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Other</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='3' valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Common Stock</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Paid-in</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Comprehensive</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Retained</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Stockholders'</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'></td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Shares</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Amount</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Capital</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Income (Loss)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Earnings</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Equity</p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at December 31, 2021</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E21_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>841</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,054</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>115,314</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,138</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='Shares' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>19</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>19</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>506</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> (<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>506</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,060</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,060</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,534</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,534</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at March 31, 2022</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E22Q1_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>903</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q1_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,560</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>117,789</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>109,168</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='Shares' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>40</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>40</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Common stock purchased and retired</span></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodShares' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>30</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y22Q2_StEqComps-AddPaidInCap' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>947</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y22Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y22Q2_StEqComps-RetainedEarnings' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,548</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y22Q2' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,495</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q2_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,298</ix:nonFraction>) </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q2' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,298</ix:nonFraction>) </p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,051</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,051</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,103</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,103</ix:nonFraction> </p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at June 30, 2022</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E22Q2_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,625</ix:nonFraction> </p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction> </p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,858</ix:nonFraction>)</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>119,293</ix:nonFraction> </p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,471</ix:nonFraction> </p>
</td></tr>
<tr style='height:25.5pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:18.7pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at December 31, 2020</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E20_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,643</ix:nonFraction></p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>115</ix:nonFraction></p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,281</ix:nonFraction>)</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>110,952</ix:nonFraction></p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>102,822</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>89</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>89</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>41</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>41</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q1_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>54</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> (<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>54</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,039</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,039</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,024</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,024</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at March 31, 2021</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E21Q1_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,646</ix:nonFraction></p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>245</ix:nonFraction></p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q1_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,335</ix:nonFraction>)</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>112,937</ix:nonFraction></p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>104,883</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='Shares' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>41</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>41</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>49</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>49</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,037</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,037</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q2_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,426</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,426</ix:nonFraction> </p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at June 30, 2021</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E21Q2_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,646</ix:nonFraction> </p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction> </p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>289</ix:nonFraction> </p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q2_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,286</ix:nonFraction>)</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>115,326</ix:nonFraction> </p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,365</ix:nonFraction> </p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:18.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>4</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a9'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>(unaudited)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0'>(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. (&quot;UTMD&quot; or &quot;the Company&quot;) annual report on Form 10 K for the year ended December 31, 2021. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
</ix:nonNumeric><p style='font:10pt CG Times;margin:0'>&#160;</p>
 <ix:nonNumeric name='us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>(2) Recent Accounting Standards. </p>
 <ix:nonNumeric name='us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.</p>
</ix:nonNumeric></ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:InventoryDisclosureTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt'>(3) Inventories at June 30, 2022 and December 31, 2021 consisted of the following:</p>
<ix:nonNumeric name='us-gaap:ScheduleOfInventoryCurrentTableTextBlock' contextRef='D220101_220630' escape='true'><table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top' style='width:411.4pt'></td><td valign='top' style='width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'> June 30, 2022</p>
</td><td valign='top' style='width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>December 31, 2021</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Finished goods</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryFinishedGoodsNetOfReserves' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,622</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryFinishedGoodsNetOfReserves' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,468</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:411.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Work-in-process</p>
</td><td valign='top' style='width:31.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:308.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryWorkInProcess' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,290</ix:nonFraction></p>
</td><td valign='top' style='width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:31.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:288.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryWorkInProcess' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,398</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Raw materials</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryRawMaterials' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,426</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryRawMaterials' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,730</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:411.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total</p>
</td><td valign='top' style='width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,338</ix:nonFraction></p>
</td><td valign='top' style='width:24.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,596</ix:nonFraction></p>
</td></tr>
</table>
</ix:nonNumeric></ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0'>(4) Stock-Based Compensation. At June 30, 2022, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, Compensation - Stock Compensation. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended June 30, 2022 and 2021, the Company recognized $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>40</ix:nonFraction> and $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>41</ix:nonFraction>, respectively, in stock based compensation cost. &#160;In the six months ended June 30, 2022 and 2021, the Company recognized $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>83</ix:nonFraction> and $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>82</ix:nonFraction>, respectively, in stock based compensation cost.</p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:ProductWarrantyDisclosureTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0'> (5) Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, <ix:nonFraction name='us-gaap:ProductWarrantyAccrual' contextRef='E21' unitRef='USD' decimals='INF' format='ixt-sec:numwordsen'><ix:nonFraction name='us-gaap:ProductWarrantyAccrual' contextRef='E22Q2' unitRef='USD' decimals='INF' format='ixt-sec:numwordsen'>no</ix:nonFraction></ix:nonFraction> warranty reserve was made at December 31, 2021 or June 30, 2022. </p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:RevenueRecognitionPolicyTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0'>(6) Global 2Q 2022 revenues (USD) by product category:</p>
<ix:nonNumeric name='fil:ScheduleOfRevenuesByProductCategoryTextBlock' contextRef='D220101_220630' escape='true'><table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top' style='width:180pt'></td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Domestic</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Outside US</p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-Obstetrics_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,006</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-Obstetrics_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>200</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-Obstetrics' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,206</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,394</ix:nonFraction></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,029</ix:nonFraction></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,423</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-Neonatal_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,514</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-Neonatal_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>399</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-Neonatal' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,913</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,915</ix:nonFraction></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,971</ix:nonFraction></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,886</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt'>Total</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,829</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,599</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,428</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Global 1H 2022 revenues (USD) by product category:</p>
<table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top' style='width:180pt'></td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Domestic</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Outside US</p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-Obstetrics_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,929</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-Obstetrics_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>326</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-Obstetrics' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,255</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,975</ix:nonFraction></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,550</ix:nonFraction></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,525</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-Neonatal_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,096</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-Neonatal_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>690</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-Neonatal' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,786</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,813</ix:nonFraction></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,373</ix:nonFraction></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,186</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt'>Total</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>15,813</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,939</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>25,752</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
</ix:nonNumeric></ix:nonNumeric><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>5</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><ix:nonNumeric name='us-gaap:IntangibleAssetsDisclosureTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0'>(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie&#174; Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $<ix:nonFraction name='us-gaap:FinitelivedIntangibleAssetsAcquired1' contextRef='Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21,000</ix:nonFraction> purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;A expenses over a remaining <ix:nonFraction name='fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' contextRef='D220630_DistributionRightsAcquisition-CoopersurgicalInc' unitRef='Pure' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.33</ix:nonFraction> year life as of June 30, 2022 of the prior CSI distribution agreement with Femcare.</p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<span style='font-family:Times New Roman;color:#000000'> </span><ix:nonNumeric name='us-gaap:EarningsPerShareTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0'>(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0'> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:12.5pt'><td valign='top' style='width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><i>(in thousands)</i></p>
</td><td colspan='3' valign='top' style='width:349pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Three months ended</p>
</td><td valign='top' style='width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td colspan='3' valign='top' style='width:349.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Six months ended</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='3' valign='top' style='width:349pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>June 30,</p>
</td><td valign='top' style='width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td colspan='3' valign='top' style='width:349.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>June 30,</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:374.95pt;padding-right:5.75pt'></td><td valign='middle' style='width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2022</p>
</td><td valign='top' style='width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2021</p>
</td><td valign='top' style='width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2022</p>
</td><td valign='top' style='width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2021</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><b>Numerator</b></p>
</td><td valign='top' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.2pt'><td valign='top' style='width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net income</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,103</ix:nonFraction></p>
</td><td valign='top' style='width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y21Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,426</ix:nonFraction></p>
</td><td valign='top' style='width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D220101_220630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,638</ix:nonFraction></p>
</td><td valign='top' style='width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D210101_210630' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,450</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:12pt'><td valign='top' style='width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><b>Denominator</b></p>
</td><td valign='top' style='width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:164.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Weighted average shares, basic</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y22Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,643</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y21Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,646</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D220101_220630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,649</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D210101_210630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,645</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Dilutive effect of stock options</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='Y22Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>7</ix:nonFraction></p>
</td><td valign='top' style='width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='Y21Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>9</ix:nonFraction></p>
</td><td valign='top' style='width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='D220101_220630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>9</ix:nonFraction></p>
</td><td valign='top' style='width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='D210101_210630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>11</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Diluted shares</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y22Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,650</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y21Q2' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D220101_220630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,658</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D210101_210630' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,656</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.75pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per share, basic</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y22Q2' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.13</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y21Q2' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.94</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D220101_220630' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.09</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D210101_210630' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.77</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:374.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per share, diluted</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y22Q2' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.12</ix:nonFraction></p>
</td><td valign='top' style='width:20pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y21Q2' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.94</ix:nonFraction></p>
</td><td valign='top' style='width:22.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D220101_220630' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.09</ix:nonFraction></p>
</td><td valign='top' style='width:19.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:164.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D210101_210630' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.76</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name='us-gaap:SubsequentEventsTextBlock' contextRef='D220101_220630' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.</p>
</ix:nonNumeric><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>6</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a10'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 2.</b> &#160;<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>General</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. &#160;The Company&#8217;s Form 10-K Annual Report for the year ended December 31, 2021 provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. &#160;Because of the relatively short span of time, results for any given three or six month period in comparison with a previous three or six month period may not be indicative of comparative results for the year as a whole. Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. &#160;Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&#160;or GBP = UK Pound Sterling; CAD = Canadian Dollars; and &#8364;&#160;or EUR = Euros. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Analysis of Results of Operations</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>a) &#160;Overview&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Income statement results in 2Q and 1H 2022 compared to the same periods of 2021 were as follows:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:231.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2022</span></p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>change</span></p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2022</span></p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td><td valign='top' style='width:76.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:231.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net Sales</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 13,428</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,604</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>+6.5%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 25,752</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 23,568</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>+9.3%</p>
</td></tr>
<tr><td valign='top' style='width:231.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gross Profit</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8,151</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,785</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4.7%</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>15,683</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>14,732</p>
</td><td valign='top' style='width:76.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>6.5%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:231.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating Income</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,057</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,765</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>6.1%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>9,579</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8,652</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>10.7%</p>
</td></tr>
<tr><td valign='top' style='width:231.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>Income Before Tax</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,199</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,825</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7.7%</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>9,729</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8,723</p>
</td><td valign='top' style='width:76.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>11.5%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:231.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>Net Income (US GAAP) </p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,103</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,426</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>19.7%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,638</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>6,450</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>18.4%</p>
</td></tr>
<tr><td valign='top' style='width:231.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per Diluted Share </p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1.124</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 0.937</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>19.9%</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 2.088</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1.765</p>
</td><td valign='top' style='width:76.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>18.3%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The comparisons of 2Q and 1H 2022 results with the results in the same periods of 2021, according to U.S. Generally Accepted Accounting Principles (US GAAP), were affected by a long term deferred tax liability increase on the balance of Femcare intangible assets (the amortization of which is not tax-deductible in the UK) in 2Q 2021. &#160;The 2Q 2021 $390 increase in deferred UK taxes over the next five years resulted from the fact that the UK decided to increase its corporate income tax rate from 19% to 25% beginning on April 1, 2023. &#160;Therefore, the remaining amortization of Femcare intangible assets from April 1, 2023 through March 11, 2026 will have a 6% ($390) higher income tax impact. &#160;According to US GAAP, a deferred tax liability increase must be booked in the quarter in which the tax law change is enacted. UTMD management believes that the presentation of results excluding the unfavorable deferred tax liability adjustments to its 2021 income tax provisions provides meaningful supplemental information to both management and investors that is more clearly indicative of UTMD&#8217;s operating results in 2022 compared to 2021. Please note that the non-US GAAP exclusion of tax provision adjustments only affects Net Income and Earnings Per Diluted Share (EPS), as follows:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:231.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right'>2Q 2022</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2Q 2021</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right'>1H 2022</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1H 2021</p>
</td><td valign='top' style='width:76.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:231.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>Net Income (non-US GAAP) </p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,103</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,817</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>+7.5%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,638</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>6,840</p>
</td><td valign='top' style='background-color:#CCEEFF;width:76.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>+11.7%</p>
</td></tr>
<tr><td valign='top' style='width:231.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EPS &#160;(non-US GAAP) </p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1.124</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1.044</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7.7%</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 2.088</p>
</td><td valign='top' style='width:76.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1.871</p>
</td><td valign='top' style='width:76.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>11.6%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The non-US GAAP comparisons of Net Income and EPS with the prior year&#8217;s same periods were consistent with the Income Before Tax comparisons. &#160;Income Before Tax obviously is not affected by income tax provisions.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Consolidated USD sales were 6.5% higher in 2Q 2022 and 9.3% higher in 1H 2022 higher compared to the same periods in 2021, despite the fact that sales invoiced in foreign currencies in 2022 were hindered by a stronger USD compared to other currencies. An unfavorable foreign currency exchange (FX) rate impact decreased total consolidated 2Q 2022 USD sales by 3.3% ($456) and 1H 2022 sales by 2.3% ($608). Sales invoiced in foreign currencies represented 29% of total consolidated sales (when expressed in USD) during 2Q 2022, and 26% during 1H 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Sales in all product categories, except for sales of the Filshie Clip System which declined in the U.S., were up in 2Q and 1H 2022 compared to the same periods in 2021.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>U.S. domestic sales in 2Q 2022 were 2.4% lower than in 2Q 2021, and 6.8% higher in 1H 2022 than in 1H 2021. &#160;Sales in 2Q 2022 to customers outside the U.S. (OUS) were 22.2% higher in USD terms, but 32.2% higher using the same FX rates as in 2Q 2021 (&#8220;constant currency&#8221;). &#160;&#160;Sales in 1H 2022 to OUS customers were 13.4% higher in USD terms, but 20.4% higher in constant currency. &#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>7</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>Gross profits (GP) increased less than revenues primarily due to inflation in the variable costs of manufacturing, despite better absorption of fixed manufacturing overhead costs with higher sales. &#160;On the Operating Income line, the lower GP margins (GP divided by sales) in both 2Q and 1H periods were offset by the impact of a stronger USD on the foreign currency expenses of UTMD&#8217;s overseas subsidiaries, as well as better absorption of USD fixed  identifiable intangible asset (IIA) amortization expenses which resulted from UTMD&#8217;s February 2019 acquisition of CooperSurgical Inc&#8217;s (CSI&#8217;s) U.S. exclusive distribution rights for the Filshie Clip System. &#160;Operating Income represented 37.7% of sales in 2Q 2022 compared to 37.8% of sales in 2Q 2021, and 37.2% of sales in 1H 2022 compared to 36.7% of sales in 1H 2021.  UTMD was able to maintain consistent Operating Income margins despite the lower GPMs and litigation expenses which it did not have in the prior year. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net Income and Earnings per Diluted Share (EPS) per US GAAP increased 19.7% and 19.9% respectively in 2Q 2022 compared to 2Q 2021. Net Income and EPS per US GAAP increased 18.4% and 18.3% respectively in 1H 2022 compared to 1H 2021. &#160;&#160;Non-US GAAP Net Income and EPS, which ignores the $390 additional income tax provision adjustment in 2021, increased 7.5% and 7.7% respectively in 2Q 2022 compared to a 2Q 2021 normal non-US GAAP operating result. &#160;Non-US GAAP Net Income and EPS increased 11.7% and 11.6% respectively in 1H 2022 compared to a 1H 2021 non-US GAAP operating result. &#160;The non-US GAAP increases in operating income were greater than the increases in sales as a result of $82 higher non-operating income in 2Q 2022 compared to 2Q 2021, and $79 higher non-operating income in 1H 2022 compared to 1H 2021. The consolidated average income tax rates (income tax provision divided by Earnings Before Taxes) follow:</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:328.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>2Q 2022 </span></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>1H 2022 </span></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:328.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Average Consolidated Income Tax Provision Rate (US GAAP)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>21.1%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>29.0%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>21.5%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>26.1%</p>
</td></tr>
<tr><td valign='top' style='width:328.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Average Consolidated Income Tax Provision Rate (non-GAAP)</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>21.1%</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>20.9%</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>21.5%</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>21.6%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>The impact of the 2Q 2021 deferred tax adjustment is apparent when comparing the US GAAP income tax provision rates with the non-US GAAP rates.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The percentage increase in 2Q 2022 EPS compared to 2Q 2021 EPS was slightly higher than the increase in Net Income because of shares repurchased in 2Q 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD profit margins in 2Q 2022 and 1H 2022 compared to 2Q 2021 and 1H 2021 follow:</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:328.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>2Q 2022 </p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>(Apr &#8211;&#160;Jun)</span></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'>2Q 2021</p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>(Apr &#8211;&#160;Jun)</span></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1H 2022 </p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>(Jan &#8211;&#160;Jun)</span></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'>1H 2021</p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>(Jan &#8211;&#160;Jun)</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:328.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (gross profits/ sales):</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>60.7%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>61.8%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>60.9%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>62.5%</p>
</td></tr>
<tr><td valign='top' style='width:328.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (operating profits/ sales):</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>37.7%</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>37.8%</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>37.2%</p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>36.7%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:328.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income Margin &#160;(US GAAP):</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>30.6%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>27.2%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>29.7%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>27.4%</p>
</td></tr>
<tr><td valign='top' style='width:328.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><i>Net Income Margin (Non-US GAAP, B4 DTL Adj):</i></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><i>30.6%</i></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><i>30.3%</i></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><i>29.7%</i></p>
</td><td valign='top' style='width:90.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><i>29.0%</i></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:690.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>Note: &#160;The Net Income Margin is Net Income after subtracting a provision for income taxes divided by sales.</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s June 30, 2022 Balance Sheet continued strong, with no debt. Ending Cash and Investments were $66.2 million on June 30, 2022 compared to $61.0 million on December 31, 2021. &#160;The June 30, 2022 cash balance resulted after paying $1.1 million in cash dividends to stockholders and repurchasing $2.5 million in UTMD stock during 2Q 2022. During the last twelve months (TTM) since June 30, 2021, UTMD has returned $12,943 to stockholders in the form of cash dividends and UTMD share repurchases.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 2Q 2022 compared to the end of calendar year 2021 and the end of 2Q 2021 were</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:118.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>6-30-22</span></p>
</td><td valign='top' style='width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>12-31-21</span></p>
</td><td valign='top' style='width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td><td valign='top' style='width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>6-30-21</span></p>
</td><td valign='top' style='width:114.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:118.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.21601</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.35358</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(10.2%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.38065</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(11.9%)</p>
</td></tr>
<tr><td valign='top' style='width:118.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.04657</p>
</td><td valign='top' style='width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.13765</p>
</td><td valign='top' style='width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(8.0%)</p>
</td><td valign='top' style='width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.18514</p>
</td><td valign='top' style='width:114.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(11.7%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:118.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.69042</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.72678</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(5.0%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.74952</p>
</td><td valign='top' style='background-color:#CCEEFF;width:114.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(7.9%)</p>
</td></tr>
<tr><td valign='top' style='width:118.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.77691</p>
</td><td valign='top' style='width:114.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.79016</p>
</td><td valign='top' style='width:114.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(1.7%)</p>
</td><td valign='top' style='width:114.4pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.80619</p>
</td><td valign='top' style='width:114.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(3.6%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>b) &#160;Revenues&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Terms of sale are established in advance of UTMD&#8217;s acceptance of customer orders. In the U.S., Ireland, UK, France, Canada, Australia and New Zealand, UTMD accepts orders directly from and ships directly to end user medical facilities, as well as third party medical/surgical distributors, under UTMD&#8217;s Standard Terms and Conditions (T&amp;C) of Sale. UTMD&#8217;s T&amp;C of Sale to end user facilities are substantially the same in the U.S. and OUS. UTMD also has standard T&amp;C of Sale for OEM customers, other medical device and non-medical device customers for components manufactured by UTMD, which are substantially the same, except that prices are generally quoted prior to acceptance of each order.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>8</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>UTMD may have separate discounted pricing agreements with a specific clinical facility, or group of affiliated facilities or large OEM customers based on volume of purchases. &#160;Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities or OEM customers, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year. For new customers, the customer&#8217;s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements based on volume of purchases disclosure is not inconsistent with UTMD&#8217;s disclosure that the selling price is fixed prior to the acceptance of a specific customer order. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>2Q 2022 Sales</span></p>
<p style='font:10pt Times New Roman;margin:0'>Total consolidated 2Q 2022 UTMD worldwide (WW) sales were $824 (+6.5%) higher than in 2Q 2021. Without the negative impact of a stronger USD in converting foreign currency sales, WW constant currency sales were $1,280 higher (+10.2%) than in 2Q 2021, which was the second highest sales quarter of 2021. &#160;&#8220;Constant currency&#8221; sales means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Overall 2Q 2022 U.S. domestic sales were 2.4% lower and outside the U.S. (OUS) sales were 22.2% higher, despite an FX rate $456 (10.6%) negative impact on sales invoiced in foreign currencies. In other words, 2Q 2022 constant currency OUS sales were 32.2% higher than in 2Q 2021. In 2021, U.S. domestic sales recovered from the COVID-19 pandemic faster than OUS sales. &#160;In 2022, it appears that OUS sales are catching up with the U.S. recovery.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Domestic U.S. sales in 2Q 2022 were $7,829 compared to $8,023 in 2Q 2021. &#160;Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct non-Filshie device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;domestic Filshie device sales&#8221;. UTMD separates domestic Filshie device sales from other medical device sales direct to medical facilities because UTMD is simply a distributor for Femcare in the U.S. &#160;Direct non-Filshie device sales, representing 51% of total domestic sales, were $266 (+7.1%) higher in 2Q 2022 than in 2Q 2021. Domestic OEM sales, representing 34% of total domestic sales, were $16 (0.6%) lower. Domestic Filshie device sales, representing 15% of total domestic sales, were $444 (27.9%) lower in 2Q 2022 compared to 2Q 2021.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OUS sales in 2Q 2022 were $5,599 compared to $4,581 in 2Q 2021. The increase in USD-denominated OUS sales is understated in constant currency terms. &#160;The stronger USD subtracted $456 from 2Q 2022 OUS sales invoiced in GBP, EUR, AUD and CAD currencies. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 2Q 2022 and 2Q 2021 for revenue purposes follow: &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>2Q 2022</span></p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.2525</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.3986</p>
</td><td valign='top' style='background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(10.4%)</p>
</td></tr>
<tr><td valign='top' style='width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.0571</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.2043</p>
</td><td valign='top' style='width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(12.2%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7178</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7696</p>
</td><td valign='top' style='background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(6.7%)</p>
</td></tr>
<tr><td valign='top' style='width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7847</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.8119</p>
</td><td valign='top' style='width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(3.4%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The weighted average unfavorable impact on 2Q 2022 foreign currency OUS sales was 10.6%. &#160;In constant currency terms, foreign currency sales in 2Q 2022 were 32.2% higher than in 2Q 2021. The portion of OUS sales invoiced in foreign currencies in USD terms were 29% of total consolidated 2Q 2022 sales compared to 27% in 2Q 2021. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. &#160;Export sales from the U.S. to OUS distributors are invoiced in USD. &#160;Direct to end-user OUS 2Q 2022 sales in USD terms (including the negative impact of FX rate differences) were 11% lower in Ireland with the EUR FX rate down 12%, 1% lower in Canada with the CAD FX rate down 3%, about the same in the UK with the GBP FX rate down 10%, 23% lower in Australia/New Zealand with the AUD FX rate down 7%, and 15% higher in France with the EUR FX rate down 12%. Sales to OUS distributors were 41% higher in 2Q 2022 than in 2Q 2021. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><span style='border-bottom:1px solid #000000'>1H 2022 Sales</span></p>
<p style='font:10pt Times New Roman;margin:0'>Total consolidated 1H 2022 UTMD WW sales were $2,184 (+9.3%) higher than in 1H 2021. Constant currency sales were $2,792 (+11.8%) higher. &#160;U.S. domestic sales were 6.8% higher and OUS sales were 13.4% higher in 1H 2022 compared to 1H 2021. In constant currency terms, 1H 2022 OUS sales were up 20.4%. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Domestic U.S. sales in 1H 2022 were $15,813 compared to $14,805 in 1H 2021. &#160;Direct non-Filshie device sales, representing 51% of total domestic sales, were $859 (+12.0%) higher in 1H 2022 than in 1H 2021, led by an increase in domestic neonatal device sales. OEM sales, representing 34% of total domestic sales, were $767 (+16.7%) higher. &#160;Domestic Filshie device sales, representing 15% of total domestic sales, were $618 (20.1%) lower in 1H 2022 compared to 1H 2021. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>9</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>OUS sales in 1H 2022 were $9,938 compared to $8,762 in 1H 2021. The increase in USD-denominated OUS sales is understated in constant currency terms. &#160;The stronger USD subtracted $608 from 1H 2022 OUS sales invoiced in GBP, EUR, AUD and CAD currencies. The transaction-weighted average FX rates from the applicable foreign currency to USD during 1H 2022 and 1H 2021 for revenue purposes follow: &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>1H 2022</span></p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td><td valign='top' style='width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.2886</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.3908</p>
</td><td valign='top' style='background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(7.3%)</p>
</td></tr>
<tr><td valign='top' style='width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.0852</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.2037</p>
</td><td valign='top' style='width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(9.8%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7206</p>
</td><td valign='top' style='background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7711</p>
</td><td valign='top' style='background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(6.6%)</p>
</td></tr>
<tr><td valign='top' style='width:171.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.7866</p>
</td><td valign='top' style='width:171.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.8009</p>
</td><td valign='top' style='width:175.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(1.8%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The weighted-average FX rate negative impact on 1H 2022 foreign currency OUS sales was 8.3%. In constant currency terms, foreign currency sales in 1H 2022 were 20.4% higher than in 1H 2021. The portion of OUS sales invoiced in foreign currencies in USD terms were 26% of total consolidated 1H 2022 sales compared to 27% in 1H 2021. Direct to end-user OUS 1H 2022 sales in actual USD terms were 5% higher in Ireland with a 10% lower EUR, 8% lower in Canada with a 2% lower CAD, 3% lower in France with a 10% lower EUR, 23% higher in the UK with a 7% lower GBP, and 28% lower in Australia/New Zealand with a 7% lower AUD. &#160;Sales to OUS distributors were 24% higher in 1H 2022 than in 1H 2021.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The following table provides USD-denominated sales amounts divided into general product categories for total revenues and the subset of OUS revenues:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Global revenues by product category:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2022</span></p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2022</span></p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 1,206</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 1,159</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 2,255</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 2,176</p>
</td></tr>
<tr><td valign='top' style='width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/ Electrosurgery/ Urology</p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,423</p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,674</p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>10,525</p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>10,802</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,913</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,642</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,786</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,229</p>
</td></tr>
<tr><td valign='top' style='width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories*</p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>4,886</span></p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>4,129</span></p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9,186</span></p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>7,361</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 13,428</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,604</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 25,752</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 23,568</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>10</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>OUS revenues by product category:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2022</span></p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2022</span></p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 200</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 213</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 326</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 326</p>
</td></tr>
<tr><td valign='top' style='width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/ Electrosurgery/ Urology</p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,029</p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,801</p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,550</p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,316</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>399</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>339</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>690</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>753</p>
</td></tr>
<tr><td valign='top' style='width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories*</p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1,971</span></p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1,228</span></p>
</td><td valign='top' style='width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3,373</span></p>
</td><td valign='top' style='width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2,368</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:304.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 5,599</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 4,581</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.55pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 9,939</p>
</td><td valign='top' style='background-color:#CCEEFF;width:96.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 8,763</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:37.8pt'></kbd>* includes assemblies and molded components sold to OEM customers.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD continues to be assembly labor limited in the U.S., in addition to continuing supply chain disruption worldwide for timely providing raw materials needed in manufacturing operations. &#160;Also, a continued strengthening of the USD would create a drag on improved 2H 2022 OUS foreign currency sales. &#160;Looking forward, without any additional price increases for UTMD devices (which is unlikely based on continuing cost increases), if UTMD is able to duplicate its 1H 2022 revenues in the 2H, sales for the 2022 year would be up about 5% compared to the 2021 year.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>c) &#160;Gross Profit (GP)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>GP results from subtracting the costs of production, manufacturing engineering, depreciation of equipment, maintenance and repairs, quality assurance including regulatory compliance, and purchasing including freight for receiving materials from suppliers. As expected, despite dilution of fixed overhead costs from higher sales, the 2Q and 1H significant inflationary increases in UTMD&#8217;s variable manufacturing costs squeezed UTMD&#8217;s GP Margin (GPM). UTMD&#8217;s 2Q 2022 GP was $365 (+4.7%) higher than in 2Q 2021. UTMD&#8217;s 1H 2022 GP was $951 (+6.5%) higher than in 1H 2021. &#160;Although revenue was up more than GP in both 1Q and 1H periods, the resulting lower GPMs remained consistent with UTMD&#8217;s long term profitability goals. &#160;Incremental direct labor costs increased significantly as a result of competition for a limited number of people currently seeking work, and the Company&#8217;s efforts to help mitigate the negative impact of inflation on its long-term employees. UTMD also experienced double-digit percentage cost increases in raw materials costs. &#160;Incoming freight costs to receive raw materials doubled. The growing administrative burden of compliance with regulatory requirements, particularly OUS, continued to pressure UTMD&#8217;s GPM. &#160;Although managing the rapid rise in variable manufacturing costs will apparently continue to be a significant challenge for the rest of 2022, the 1H 2022 GPM helps confirm that UTMD is likely to be able to successfully manage it. &#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>11</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>d) &#160;Operating Income &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Operating Income results from subtracting Operating Expenses (OE) from GP. After subtracting OE from higher 2Q and 1H 2022 GP, Operating Income in 2Q 2022 was $5,057 compared to $4,765 in 2Q 2021, an increase of 6.1%, representing a healthy Operating Income Margin (Operating Income as a percentage of sales) of 37.7%. &#160;Operating Income in 1H 2022 was $9,579 compared to $8,652 in 1H 2021, an increase of 10.7%, representing an Operating Income Margin of 37.2%. &#160;The increase in Operating Income was almost the same as the increase in sales despite a lower GPM and higher litigation expenses (included in G&amp;A OE) because of two offsetting factors; 1) better absorption of fixed IIA amortization expenses (i.e. a lower percentage of sales for relatively fixed non-cash expenses), and 2) a reduction in USD-denominated foreign currency OE of foreign subsidiaries as a result of a stronger USD (i.e. lower FX rates for the EUR, GBP, AUD and CAD expenses).</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OE are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses. The following table summarizes OE in 2Q and 1H 2022 compared to the same periods in 2021 by OE category:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>OE Category</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2022</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2022</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>S&amp;M:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;357</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2.7</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;364</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2.9</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;693</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2.7</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;748</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.2</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>G&amp;A:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,602</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>19.3</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,528</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>20.1</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,153</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>20.0</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,073</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>21.5</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>R&amp;D:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>135</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1.0</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>128</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1.0</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>258</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1.0</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>259</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1.1</span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total OE:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,094</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>23.0</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,020</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>24.0</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 6,104</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>23.7</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 6,080</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>25.8</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>A stronger USD helped decrease foreign currency OE when converted to USD by $100 in 2Q 2022 and $135 in 1H 2022. The following table summarizes &#8220;constant currency&#8221; OE in 2Q and 1H 2022 compared to the same periods in 2021 by OE category:</p>
<p style='font:10pt Times New Roman;margin:0'> &#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>OE Category</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2022 const FX</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2022 const FX</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>S&amp;M:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;366</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;364</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;707</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;748</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>G&amp;A:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,693</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,528</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,274</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,073</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>R&amp;D:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>135</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>128</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>258</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>259</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total OE:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,194</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,020</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 6,239</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 6,080</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OUS OE when converted to USD were decreased 10% in 2Q 2022 and 7% in 1H 22 by the FX rate change. Constant currency 2Q 2022 OE were 6% higher than in 2Q 2021, and 3% higher in 1H 2022 than in 1H 2021. In other words, the FX rate change which decreased foreign OE in USD terms almost offset the higher G&amp;A expenses in the U.S. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The change in FX rates decreased 2Q 2022 OUS S&amp;M expenses by $9, and 1H 2022 OUS S&amp;M expense by $14. The lower constant currency S&amp;M expenses were due primarily to a reduction of outside sales representatives in the UK. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>A segmentation of USD-denominated G&amp;A expenses by subsidiary location follows. Note that over 60% of G&amp;A expenses were non-cash expenses from the amortization of IIA associated with the Filshie Clip System:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>G&amp;A Expense Category</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2022</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2022</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>% of sales</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>IIA Amort&#8211; UK:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;498</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3.7</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;556</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4.4</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,030</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4.0</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,106</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4.7</p>
</td></tr>
<tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>IIA Amort&#8211; CSI:</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,105</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8.2</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,105</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8.8</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,210</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8.6</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,210</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>9.4</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Other&#8211; UK:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>142</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>155</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>296</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>312</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>U.S. Litigation:</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>165</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>-</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>226</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>-</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Other&#8211; US:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>528</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>552</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>1,082</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>1,113</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>IRE:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>85</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>77</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>152</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>161</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUS:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>42</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>42</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>85</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>88</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>CAN:</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>37</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>41</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>72</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>83</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total G&amp;A:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 2,602</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>19.3</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 2,528</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>20.1</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 5,153</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>20.0</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 5,073</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>21.5</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OUS G&amp;A expenses were $804 in 2Q 2022 compared to $871 in 2Q 2021. OUS G&amp;A expenses were $1,634 in 1H 2022 compared to $1,750 in 1H 2021. &#160;The table below identifies &#8220;constant currency&#8221; OUS G&amp;A expenses for 2Q and 1H 2022 compared to the same periods in 2021:</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>12</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>G&amp;A Expense Category</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2022 const FX</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2022 const FX</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>IIA Amort&#8211; UK:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;556</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;556</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,106</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,106</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Other&#8211; UK:</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>159</span></p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>155</span></p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>318</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>312</span></p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>IRE:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>97</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>77</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>168</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>161</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUS:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>44</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>42</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>91</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>88</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>CAN:</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>38</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>41</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>73</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>83</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:221.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total G&amp;A:</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 894</p>
</td><td valign='top' style='width:53.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 871</p>
</td><td valign='top' style='width:53.95pt;padding-right:5.75pt;border-right:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:1.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 1,756</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:63.35pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 1,750</p>
</td><td valign='top' style='width:63.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Period to period product development (R&amp;D) expenses varied slightly depending on specific project costs. Since almost all R&amp;D is being carried out in the U.S., there was negligible FX rate impact.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>e) &#160;Non-operating expense/ Non-operating income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Non-operating expense includes bank fees and expenses from losses, if applicable, from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms. &#160;Non-operating income includes 1) income from rent of underutilized property, 2) investment income (interest on cash balances), 3) royalties received from licensing the Company&#8217;s technology, and 4) income from gains, if applicable, from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms. Non-operating income or expense can also include gains or losses from the disposition of assets from time to time. Net non-operating income is non-operating income minus non-operating expense during a particular time period. Net non-operating income in 2Q 2022 was $142 compared to $60 in 2Q 2021.  Net non-operating income in 1H 2022 was $150 compared to $71 in 1H 2021. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The main difference in net non-operating income during both 2Q and 1H 2022 was due to greater rental income received from renting underutilized warehouse space in Ireland to a third party, and to more interest received on cash bank balances. Because UTMD owns its own facilities with space in excess of current needs, this sort of opportunistic rental income occurs from time to time. UTMD Ireland realized $17 more in 2Q 2022 rental income than in 2Q 2021, and $69 more in 1H 2022 rental income than in 1H 2021. &#160;With higher cash balances and higher interest rates in 2022 compared to 2021, UTMD received $90 more in 2Q 2022 interest income and $34 more in 1H interest income.  In 2Q 2022, a loss of $2 on remeasured foreign currency balances was recognized compared to a gain of $5 in 2Q 2021. &#160;In both 1H 2022 and 1H 2021, a loss of $5 on remeasured foreign currency balances was recognized. &#160;Royalties received were $5 in 2Q 2022 and $10 in 1H 2022 compared to $0 in both 2Q and 1H 2021. &#160;Bank fees were $25 in 2Q 2022 compared to $18 in 2Q 2021. &#160;Bank fees were $49 in 1H 2022 compared to $35 in 1H 2021.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>f) &#160;Income Before Income Taxes (EBT)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Consolidated EBT results from subtracting net non-operating expense or adding net non-operating income from or to, as applicable, Operating Income. &#160;Consolidated 2Q 2022 EBT was $5,199 (38.7% of sales) compared to $4,825 (38.3% of sales) in 2Q 2021. Consolidated 1H 2022 EBT was $9,729 (37.8% of sales) compared to $8,723 (37.0% of sales) in 1H 2021.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The EBT of Utah Medical Products, Inc. in the U.S. was $5,981 in 1H 2022 compared to $5,466 in 1H 2021. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 3,825 in 1H 2022 compared to EUR 3,122 in 1H 2021. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was (GBP 232) in 1H 2022 compared to (GBP 295) in 1H 2021. &#160;The EBT of Utah Medical Products Canada, Inc. (dba Femcare Canada) was CAD 332 in 1H 2022 compared to CAD 303 in 1H 2021. EBT of subsidiaries includes the result of intercompany shipments which are netted out of consolidated results.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance, as well as its ability to sustain performance during a challenging economic time. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2022 consolidated EBT excluding the remeasured bank balance currency gain or loss (&#8220;adjusted consolidated EBITDA&#8221;) was $7,005 (+4.6%) compared to $6,695 in 2Q 2021. &#160;Adjusted consolidated EBITDA at $13,376 in 1H 2022 was 7.3% higher compared to $12,471 in 1H 2021. Adjusted consolidated TTM EBITDA was $27,435 as of June 30, 2022. &#160;TTM EBITDA as of June 30, 2021, a year earlier, was $3,411 lower.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA as a percentage of sales (EBITDA margin) was 52.2% in 2Q 2022 compared to 53.1% in 2Q 2021. UTMD&#8217;s EBITDA margin was 51.9% in 1H 2022 compared to 52.9% in 1H 2021. The lower 2022 EBITDA margins reflect the 2022 GPM squeeze. Nevertheless, management believes that current EBITDA margins demonstrate continued outstanding operating performance. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>13</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:330.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2022</span></p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2Q 2021</span></p>
</td><td valign='top' style='width:86.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2022</span></p>
</td><td valign='top' style='width:86.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1H 2021</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:330.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EBT</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;5,199</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;4,825</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;9,729</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;8,723</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:330.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Depreciation Expense</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>153</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>162</p>
</td><td valign='top' style='width:86.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>302</p>
</td><td valign='top' style='width:86.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>326</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:330.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>498</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>556</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,030</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,106</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:330.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CSI IIA Amortization Expense</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1,105</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1,105</p>
</td><td valign='top' style='width:86.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 2,211</p>
</td><td valign='top' style='width:86.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 2,211</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:330.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 8</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 10</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 16</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 18</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:330.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Stock Option Compensation Expense</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 40</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 41</p>
</td><td valign='top' style='width:86.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 83</p>
</td><td valign='top' style='width:86.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 82</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:330.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Interest Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:330.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2</p>
</td><td valign='top' style='width:79.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(4)</p>
</td><td valign='top' style='width:86.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5</p>
</td><td valign='top' style='width:86.25pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:330.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>UTMD non-US GAAP EBITDA:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 7,005</p>
</td><td valign='top' style='background-color:#CCEEFF;width:79.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 6,695</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 13,376</p>
</td><td valign='top' style='background-color:#CCEEFF;width:86.25pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,471</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Note</span></p>
<p style='font:10pt Times New Roman;margin:0'>All UTMD income statement measures from GP through EBT, including non-US GAAP adjusted consolidated EBITDA, for both 2022 and 2021 time periods were unaffected by the 2Q 2021 enacted change in the UK corporate income tax rate.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>g) &#160;Net Income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net Income in 2Q 2022 of $4,103 (30.6% of sales) was 19.7% higher than the US GAAP Net Income of $3,426 (27.2% of sales) in 2Q 2021. &#160;Excluding the &#8220;one-time&#8221; income tax provision increase recognized in 2Q 2021 as a result of a future UK tax rate increase and resulting DTL adjustment, diluted Net Income in 2Q 2022 was $4,103 (30.6% of sales) compared to non-US GAAP Net Income of $3,817 (30.3% of sales) in 2Q 2021, a 7.7% increase, which is consistent with the increase in EBT per US GAAP. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>As a reminder, in 2Q 2021, because the UK reset its corporate tax rate from 19% to 25% beginning with 2Q 2023, it caused UTMD to have to book an additional $390 in its 2Q 2021 income tax provision that represents the additional tax which would be paid in the UK over the remaining IIA amortization life of the 2011 Femcare acquisition. Excluding the $390 DTL increase in 2Q 2021 which reduced Net Income by that same amount, 2Q 2021 non-US GAAP Net Income was $3,817 (30.3% of sales) compared to 2Q 2021 US GAAP Net Income of $3,427 (27.2% of sales). &#160;Excluding the same tax provision increase in 1H 2021 due to the DTL adjustment, non-US GAAP 1H 2021 Net Income was $6,840 (29.0% of sales), compared to US GAAP 1H 2021 Net Income of $6,450 (27.4% of sales).</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The average consolidated income tax provisions (as a % of the same period EBT) per US GAAP in 2Q 2022 and 2Q 2021 were 21.1% and 29.0% respectively, and were 21.5% and 26.1% in 1H 2022 and 1H 2021 respectively. As the tax rates for 2Q and 1H 2021 are not directly related to EBT generated in the same periods, UTMD provides the following tax rates excluding the 2Q 2021 $390 tax provision adjustment: The resulting non-GAAP income tax provision rates were 21.1% and 20.9% for 2Q 2022 and 2Q 2021 respectively, and were 21.5% and 21.6% for 1H 2022 and 1H 2021 respectively. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. The basic corporate income tax rates in each of the sovereignties were the same as in the prior year.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>h) &#160;Earnings Per Share (EPS)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EPS are consolidated Net Income divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are &#8220;in the money,&#8221; i.e., have exercise prices below the applicable period&#8217;s weighted average market value). Diluted EPS in 2Q 2022 were $1.124 compared to US GAAP diluted EPS of $0.937 in 2Q 2021, a 19.9% increase. &#160;Excluding the &#8220;one-time&#8221; income tax provision increase recognized in 2Q 2021 as a result of a future UK tax rate increase and a DTL adjustment, diluted EPS in 2Q 2022 were $1.124 compared to non-US GAAP diluted EPS of $1.044 in 2Q 2021, 7.7% higher, consistent with the increase in EBT.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Diluted EPS in 1H 2022 were $2.088 compared to US GAAP diluted EPS of $1.765 in 1H 2021, an 18.3% increase. &#160;Excluding the &#8220;one-time&#8221; income tax provision increase recognized in 2Q 2021 as a result of a future UK tax rate increase and a DTL adjustment, diluted EPS in 1H 2022 were $2.088 compared to non-US GAAP diluted EPS of $1.871 in 1H 2021, an 11.6% increase, also consistent with the increase in EBT per US GAAP. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Diluted shares were 3,650,242 in 2Q 2022 compared to 3,655,319 in 2Q 2021. &#160;Diluted shares were 3,657,864 in 1H 2022 compared to 3,655,514 in 1H 2021. &#160;The lower diluted shares in 2Q 2022 were the result of shares repurchased during 2Q 2022 offset by employee options exercised, and a lower dilution factor for unexercised options. The number of shares added as a dilution factor in 2Q 2022 was 7,375 compared to 9,526 in 2Q 2021. The number of shares added as a dilution factor in 1H 2022 was 9,069 compared to 10,569 in 1H 2021.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. Outstanding shares at the end of 2Q 2022 were 3,624,932 compared to 3,654,737 at the end of calendar year 2021. The difference was due to 300 shares added from employee option exercises during 1H 2022, offset by 30,105 shares repurchased in the open market and retired during 2Q 2022. For comparison, outstanding shares were 3,645,798 at the end of 2Q 2021. The total number of outstanding unexercised employee and outside director options at June 30, 2022 was 50,408 at an average exercise price of $69.07, including shares awarded but not yet vested. &#160;This compares to 63,874 unexercised option shares at the end of 2Q 2021 at an average exercise price of $68.38/ share, including shares awarded but not vested. &#160;No options were awarded in 2021 and to date in 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD paid $1,060 ($0.290/share) in dividends to stockholders in 2Q 2022 compared to $1,039 ($0.285/ share) paid in 2Q 2021. The dividends paid to stockholders during 2Q 2022 were 26% of NI. UTMD paid $1,060 ($0.290/share) in dividends to stockholders in 1H 2022 compared to $2,077 ($0.285/ share) paid in 1H 2021. The 1H 2022 dividend total excludes a dividend normally paid in January. A special dividend of $7,309 ($2.00/share) was paid in December 2021 in lieu of January 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In 2Q 2022, UTMD repurchased 30,105 of its shares for $2,495, an average cost of $82.88/ share. &#160;No UTMD shares were repurchased in 2021. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 2Q 2022 was $85.90, down 4.4% from the closing price of $89.86 at the end of 1Q 2022, and down 14.1% from the closing price of $100.00 at the end of 2021. &#160;The closing share price one year ago at the end of 2Q 2021 was $85.04. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>14</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>i) &#160;Return on Equity (ROE)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>ROE is the portion of net income retained by UTMD to internally finance its growth, divided by the average accumulated stockholders&#8217; equity for the applicable time period. &#160;Annualized ROE (using non-GAAP net income in 2021 and before stockholder dividends) in 1H 2022 was 14% compared to 13% in 1H 2021. &#160;The higher ROE in 1H 2022 was due to the higher 1H 2022 net income, despite being diluted by higher average Stockholder&#8217;s Equity. Targeting a high ROE of 20% remains a financial objective for UTMD management. &#160;ROE can be increased by increasing net income, or by reducing stockholders&#8217; equity by paying cash dividends to stockholders or by repurchasing shares. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Liquidity and Capital Resources</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>j) &#160;Cash flows&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $9,878 in 1H 2022 compared to $10,225 in 1H 2021. &#160;Although UTMD achieved a $1,187 higher increase in US GAAP Net Income in 1H 2022 and &#160;a $591 higher contribution to cash provided by a $102 decrease in accounts receivable compared to a $489 increase in 1H 2021, a $347 lower net increase in operating cash in 1H 2022 than in 1H 2021 was due to offsetting working capital change differences including 1) a $929 increase in inventories compared to a $75 decrease in 1H 2021, 2) a $357 decrease in accrued expenses compared to a $34 increase in 1H 2021, 3) a $335 smaller increase in accounts payable than in 1H 2021, and 4) a $286 decrease in deferred income taxes compared to a $22 increase in 1H 2021. &#160; &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Capital expenditures for property and equipment (PP&amp;E) were $450 in 1H 2022 compared to $222 in 1H 2021. The amount spent in 1H 2021 was for typical expenditures required to keep facilities and equipment, particularly in molding operations, in good working order. The larger capital expenditures in 1H 2022 were primarily due to purchasing new equipment and tooling needed to expand production capacity for UTMD&#8217;s largest OEM customer. Depreciation of PP&amp;E was $302 in 1H 2022 compared to $325 in 1H 2021. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD made cash dividend payments of $1,060 in 1H 2022 compared to $2,077 in 1H 2021. &#160;The difference was due to an earlier payment of a special dividend in December 2021, which in the prior year was paid in January 2021. UTMD&#8217;s normal quarterly dividend in 1H 2022 was 1.8% higher per share than in the previous year (excluding the 2021 year-end special dividend). </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In 1H 2022, UTMD received $23 and issued 300 shares of its stock upon the exercise of employee and director stock options. Option exercises in 1H 2022 were at an average price of $76.25 per share. In comparison, in 1H 2021, UTMD received $92 and issued 2,763 shares of its stock upon the exercise of employee and director stock options. Option exercises in 1H 2021 were at an average price of $33.17 per share. &#160; </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans. The Company may utilize cash not needed to support normal operations in one or a combination of the following: &#160;1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD&#8217;s existing infrastructure. &#160;If there are no better strategic uses for UTMD&#8217;s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>k) &#160;Assets and Liabilities&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>At June 30, 2022 compared to the end of 2021, UTMD&#8217;s cash and investments increased $5,249 to $66,224 primarily as a result of 1H 2022 Net Income of $7,638 less $3,555 use of cash for dividends to stockholders and UTMD share repurchases. At June 30, 2022, net Intangible Assets decreased to 22.9% of total consolidated assets from 27.2% on December 31, 2021 due in part to a stronger USD which lowers the USD value of Femcare&#8217;s GBP IIA. UTMD&#8217;s still strong 17.8 current ratio at June 30, 2022 was lower than the 19.5 current ratio at December 31, 2021 as a result of $636 higher accrued liabilities. The average age of trade receivables was 33 days from date of invoice at June 30, 2022 compared to 36 days at December 31, 2021 based on the most recent calendar quarter of sales. Average inventory turns declined slightly to 2.9 in 2Q 2022 compared to 3.0 for the last quarter of 2021 due to increasing safety stocks of raw material. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>June 30, 2022 total consolidated assets were $116,149, an increase of $513 from December 31, 2021. Current assets were $5,795 higher than at December 31, 2021 primarily because of a $5,249 increase in cash and a $741 increase in inventories. &#160;The modest increase in total assets despite the large increase in current assets was primarily due to a $4,806 decline in net intangible assets from 1H 2022 IIA amortization and a 10% lower GBP/USD FX rate on the Femcare UK intangible asset balance, in addition to a $462 USD-value decline in UK and Ireland Property and Equipment from the difference in the foreign currency exchange (FX) rate at December 31, 2021 and June 30, 2022. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>15</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>For clarity, the net book value of consolidated property, plant and equipment decreased $476 at June 30, 2022 from the end of 2021 due to the net effect of period-ending changed FX rates, $450 in new asset purchases minus $302 in depreciation, including right of use assets totaling $420 (which were $449 at December 31, 2021).</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>June 30, 2022 net intangible assets (goodwill plus other intangible assets) declined $4,806 from the end of 2021 as a result of $3,240 in amortization and a 10.2% stronger USD/GBP FX rate on UK intangible asset balances. At June 30, 2022, net intangible assets including goodwill were 23% of total consolidated assets compared to 27% at year-end 2021 and 30% at June 30, 2021. </p>
<p style='font:10pt Times New Roman;margin:0'><br/>Working capital (current assets minus current liabilities) was $74,514 at June 30, 2022 compared to $69,412 at December 31, 2021. Cash balances were $66,224 of the June 30, 2022 working capital. Current assets at June 30, 2022 compared to December 31, 2021 were $5,795 higher primarily as the result of a $5,249 increase in cash and investments and a $742 increase in inventories. Current liabilities were $693 higher at June 30, 2022 compared to December 31, 2021 as the result of a $636 increase in accrued liabilities and $57 higher accounts payable. &#160;The higher accrued liabilities resulted from no stockholder dividend, which was paid earlier than normal in December 2021, accrued at the end of 2021, whereas at the end of 2Q 2022 a $1,060 dividend, which was paid in July, was included in June 30, 2022 accrued liabilities. &#160;The increase in accrued liabilities was less than the $1,060 accrued dividend primarily because the accrued profit-sharing bonus at the end of 2021, based on 2021 full year results, was $349 higher than the profit-sharing bonus accrued at June 30, 2022 based on 6 months&#8217; results. UTMD management believes that its working capital remains more than sufficient to meet normal operating needs, new capital expenditures and projected cash dividend payments to stockholders.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>June 30, 2022 total consolidated liabilities were $8,679, an increase of $180 from December 31, 2021. Current liabilities were $693 higher than at December 31, 2021. &#160;Long term liabilities were $513 lower primarily as a result of the deferred tax liability balance resulting from non-tax deductible Femcare remaining IIA amortization expense being $397 lower.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The deferred tax liability balance for Femcare IIA ($9,084 on the date of the acquisition), was $1,707 at June 30, 2022 compared to $2,105 at December 31, 2021 and $2,355 at June 30, 2021. Reduction of the deferred tax liability occurs as the book/tax difference of amortization is eliminated over the remaining useful life of the Femcare IIA, i.e. as Femcare pays its taxes in the UK without the benefit of a deduction for IIA amortization expense. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s total debt ratio (total liabilities/total assets) as of June 30, 2022 and December 31, 2021 was 7%, compared to June 30, 2021 at 8%. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>l) &#160;Management's Outlook&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>As outlined in its December 31, 2021 SEC 10-K report, UTMD&#8217;s plan for 2022 was to</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:18pt'>1) &#160;leverage distribution and manufacturing synergies by further integrating capabilities and resources in UTMD&#8217;s multinational operations;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:18pt'>2) &#160;expand manufacturing capacity at a time when resources are particularly scarce;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:18pt'>3)  &#160;focus on effectively differentiating the benefits of the Filshie Clip System in the U.S.;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:18pt'>4)   &#160;introduce additional products helpful to clinicians through internal product development;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:18pt'>5) &#160;continue to achieve excellent overall financial operating performance;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:18pt'>6) &#160;utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued; and</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:18pt'>7) &#160;remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult burdens on small, innovative companies.</p>
<p style='font:10pt Times New Roman;margin:0'>Despite continuing economic challenges created by government reaction to the COVID-19 pandemic, especially including inflation in costs and lack of availability of workers, the Company continues to effectively execute its 2022 plan as outlined above.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>m) &#160;Accounting Policy Changes&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>None.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>16</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>Forward-Looking Information. &#160;This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. &#160;When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221; and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. &#160;Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. &#160;Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected or intended. &#160;Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. &#160;Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a11'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 3.</b> <b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and in Canada denominated in the Canadian Dollar (CAD). &#160;The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. &#160;The exchange rates were .9555, .8790 and .8438 EUR per USD as of June 30, 2022, December 31, 2021 and June 30, 2021, respectively. &#160;Exchange rates were .8224, .7388 and .7243 GBP per USD as of June 30, 2022, December 31, 2021 and June 30, 2021, respectively. &#160;Exchange rates were 1.4484, 1.3759 and 1.3342 AUD per USD on June 30, 2022, December 31, 2021 and June 30, 2021, respectively. &#160;Exchange rates were 1.2872, 1.2656, and 1.2404 CAD per USD on June 30, 2022, December 31, 2021 and June 30, 2021, respectively. UTMD manages its foreign currency risk without separate hedging transactions by either invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur and/or by optimizing global account structures through liquidity management accounts.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a12'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 4. Controls and Procedures</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The Company&#8217;s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of June 30, 2022. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of June 30, 2022, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style='font:10pt Times New Roman;margin:0;text-indent:24.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the six months ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal controls over financial reporting. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>17</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a13'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>PART II - OTHER INFORMATION</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a14'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 1. Legal Proceedings</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The Company is currently a party in litigation incidental to its business related to the safety of the Filshie Clip System, which remains approved under a PMA by the U.S. FDA as safe and effective. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a15'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 1A. Risk Factors</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#333333'>In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in UTMD&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, which could materially affect its business, financial condition or future results. &#160;The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. &#160;Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company&#8217;s business, financial condition and/or operating results.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Legislative or executive order healthcare interference in the United States</span> renders the U.S. medical device marketplace unpredictable. A fully government-run healthcare system would likely eliminate healthcare consumer choice as well as commercial incentives for innovation. &#160;Restrictions on &#8220;nonessential&#8221; medical procedures during a pandemic reduce the demand for certain of UTMD&#8217;s medical devices. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Increasing regulatory burdens, including premarketing approval delays, may result in significant loss of revenue, unpredictable costs and loss of management focus on developing and marketing products that improve the quality of healthcare: </span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>Thousands of small focused medical device manufacturers including UTMD that do not have the overhead structure that the few large medical device companies can afford are increasingly burdened with bureaucratic and underqualified regulator demands that are not reasonably related to assuring the safety or effectiveness of the devices that they provide. &#160;Premarketing submission administrative burdens, and substantial &#8220;user fees&#8221; or notified body review fees, represent a significant non-clinical and/or non-scientific barrier to new product introduction, resulting in lack of investment or delays to revenues from new or improved devices. &#160;The risks associated with such circumstances relate not only to substantial out-of-pocket costs, including potential litigation in millions of dollars, but also loss of business and a diversion of attention of key employees for an extended period of time from managing their normal responsibilities, particularly in new product development and routine quality assurance activities.  &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Group Purchasing Organizations (GPOs) in the U.S. add non-productive costs, weaken the Company&#8217;s marketing and sales efforts and cause lower revenues by restricting access:</span> &#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD&#8217;s, into undifferentiated commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. Otherwise, their business model based on &#8220;kickbacks&#8221; would be a violation of law. &#160;Despite rhetoric otherwise, these bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily driven by collection of their administrative fees. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The Company&#8217;s business strategy may not be successful in the future:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:8.55pt'></kbd>As the level of complexity and uncertainty in the medical device industry increases, evidenced, for example, by the unpredictable and overly cumbersome regulatory environment, the Company&#8217;s views of the future and product/ market strategy may not yield financial results consistent with the past.&#160;&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>18</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>As the healthcare industry becomes increasingly bureaucratic it puts smaller companies like UTMD at a competitive disadvantage: &#160;</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>An aging population is placing greater burdens on healthcare systems, particularly hospitals. The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years. &#160;Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs. &#160;As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain clinical users because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products and services. &#160;Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD&#8217;s clinical advantages more difficult. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>A product liability lawsuit could result in significant legal expenses and a large award against the Company: </span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>UTMD&#8217;s devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case. &#160;In any lawsuit where an individual plaintiff suffered permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The Company&#8217;s reliance on third party distributors in some markets may result in less predictable revenues:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>UTMD&#8217;s distributors have varying expertise in marketing and selling specialty medical devices. &#160;They also sell other devices that may result in less focus on the Company&#8217;s products. &#160;In some countries, notably China, Pakistan and India not subject to similarly rigorous standards, a distributor of UTMD&#8217;s products may eventually become a competitor with a cheaper but lower quality version of UTMD&#8217;s devices. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The loss of one or more key employees could negatively affect UTMD performance:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance. &#160;The Company&#8217;s benefits programs are key to recruiting and retaining talented employees. &#160;An increase in UTMD&#8217;s employee healthcare plan costs, for example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Fluctuations in foreign currencies relative to the USD can result in significant differences in period-to-period financial results:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>Since a significant portion of UTMD&#8217;s sales are invoiced in foreign currencies and consolidated financial results are reported in USD terms, a stronger USD can have negative revenue effects. Conversely, a weaker USD would increase foreign subsidiary operating costs in USD terms. For the portion of sales to foreign entities made in fixed USD terms, a stronger USD makes the devices more expensive and weakens demand. &#160;For the portion invoiced in a foreign currency, not only USD-denominated sales are reduced, but also gross profits may be reduced because finished distributed devices and/or U.S. made raw materials and components are likely being purchased in fixed USD.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Trade restrictions and /or tariffs resulting from changing government trade policies have the potential to disrupt UTMD&#8217;s supply chain.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The COVID-19 pandemic could continue to disrupt UTMD&#8217;s supply chain or interfere with normal business operations due to the loss of employee availability and rapidly rising input costs.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a16'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 2. &#160;Unregistered Sales of Equity Securities and Use of Proceeds</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>During 2Q 2022/ 1H 2022 UTMD purchased 30,105 of its shares in the open market for $2,495 including commissions and fees ($82.88/ share.) &#160;UTMD did not purchase any of its own securities during 1H 2021.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>19</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a1' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a17'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 6. &#160;Exhibits </b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:11.5pt'><td valign='bottom' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Exhibit #</span></p>
</td><td valign='bottom' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Title of Document</span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>31.1</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex31z1.htm' style='text-decoration:none'>Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>31.2</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex31z2.htm' style='text-decoration:none'>Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>32.1</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex32z1.htm' style='text-decoration:none'>Certification of CEO pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>32.2</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex32z2.htm' style='text-decoration:none'>Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>101</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>The following financial information from the Utah Medical Products, Inc. quarterly report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline Extensible Business Reporting Language (iXBRL): &#160;(i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Condensed Statements of Stockholders&#8217; Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>104</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a18'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>SIGNATURES</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:28.8pt'></kbd>Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:204.2pt'></kbd><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:204.2pt'></kbd>REGISTRANT&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>Date: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;8/11/22 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style='margin-left:204.2pt'></kbd>By: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Kevin L. Cornwell &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>Kevin L. Cornwell&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>CEO&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>Date: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;8/11/22 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style='margin-left:204.2pt'></kbd>By: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Brian L. Koopman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>Brian L. Koopman&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:219.1pt'></kbd>Principal Financial Officer&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>20</p>
<p style='font:14pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt CG Times;margin:0'>&#160;</p>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>utmd_ex31z1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'><B>Exhibit 31.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF CEO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Kevin L. Cornwell, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: August 11, 2022</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt CG Times;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>utmd_ex31z2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Brian L. Koopman, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-15.3pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: August 11, 2022</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Brian L. Koopman &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>utmd_ex32z1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 32.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-73.8pt;margin-left:73.8pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt Times New Roman;margin:0'>August 11, 2022</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>utmd_ex32z2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 32.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<P style='font:10pt Times New Roman;margin:0'>August 11, 2022</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>utmd-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20220630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset' xlink:label='us-gaap_OperatingLeaseRightOfUseAsset'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_OperatingLeaseRightOfUseAsset' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_Goodwill' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_Depreciation' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='8.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>utmd-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20220630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureBasisOfPresentation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureInventories"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureInventories"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureWarrantyReserve"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserve"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureRevenueRecognition"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognition"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureEarningsPerShare"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShare"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureSubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureSubsequentEvents"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensationDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserveDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>utmd-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20220630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition [Axis]</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the description of Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='lab_fil_DistributionRightsAcquisitionAxis'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DomesticUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the DomesticUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DomesticUsMember' xlink:to='lab_fil_DomesticUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_SegmentGeographicalDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_SegmentGeographicalDomain' xlink:to='lab_srt_SegmentGeographicalDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-based compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2022, 3,625 shares and December 31, 2021, 3,655 shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability - Femcare IIA</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in operating assets and liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for (recovery of) losses on accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Operating income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Goodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Goodwill</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Goodwill' xlink:to='lab_us-gaap_Goodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gynecology/Electrosurgery/Urology</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GynecologyElectrosurgeryUrologyMember' xlink:to='lab_fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllocatedShareBasedCompensationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allocated Share-based Compensation Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllocatedShareBasedCompensationExpense' xlink:to='lab_us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Inventory, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements and Changes in Accounting Principles</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization of Right of Use Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warranty Reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyDisclosureTextBlock' xlink:to='lab_us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquireIntangibleAssets' xlink:to='lab_us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:to='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finite-Lived Intangible Assets Acquired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:to='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Work-in-process</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PolicyTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Policies</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='lab_us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableCurrent' xlink:to='lab_us-gaap_AccountsPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentTransitionReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Transition Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentTransitionReport' xlink:to='lab_dei_DocumentTransitionReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductsAndServicesDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductsAndServicesDomain' xlink:to='lab_srt_ProductsAndServicesDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductOrServiceAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductOrServiceAxis' xlink:to='lab_srt_ProductOrServiceAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockOptionPlanExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockOptionPlanExpense' xlink:to='lab_us-gaap_StockOptionPlanExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:to='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_Security12bTitle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Title of 12(b) Security</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_Security12bTitle' xlink:to='lab_dei_Security12bTitle'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsGross' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Security Exchange Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Remaining years of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Remaining years of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:to='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Blood Pressure Monitoring and Accessories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BloodPressureMonitoringAndAccessoriesMember' xlink:to='lab_fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted average shares, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding - basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling, general and administrative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='lab_us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentQuarterlyReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Quarterly Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentQuarterlyReport' xlink:to='lab_dei_DocumentQuarterlyReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyAccrual' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Standard and Extended Product Warranty Accrual</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyAccrual' xlink:to='lab_us-gaap_ProductWarrantyAccrual'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of exchange rate changes on cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Sales, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:to='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Tax Identification Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaid' xlink:to='lab_us-gaap_IncomeTaxesPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payment of dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payment of dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsOfDividends' xlink:to='lab_us-gaap_PaymentsOfDividends'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total adjustments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax benefit attributable to exercise of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:to='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, diluted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherNonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherNonoperatingIncomeExpense' xlink:to='lab_us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Neonatal</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Neonatal, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NeonatalMember' xlink:to='lab_fil_NeonatalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CSI Distribution Agreement Purchase Disclosure</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:to='lab_us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding - diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:to='lab_us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:to='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of common stock - options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:to='lab_us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AmortizationOfIntangibleAssets' xlink:to='lab_us-gaap_AmortizationOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:to='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='lab_fil_DistributionRightsAcquisitionDomain'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obstetrics</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Obstetrics, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ObstetricsMember' xlink:to='lab_fil_ObstetricsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementGeographicalAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementGeographicalAxis' xlink:to='lab_srt_StatementGeographicalAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (basic)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalCommonStock' xlink:to='lab_us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLiabilitiesNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other long term liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLiabilitiesNoncurrent' xlink:to='lab_us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset' xlink:label='us-gaap_OperatingLeaseRightOfUseAsset'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAsset' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating lease - right-of-use assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAsset' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAsset'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CooperSurgical Inc</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the CooperSurgical Inc, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CoopersurgicalIncMember' xlink:to='lab_fil_CoopersurgicalIncMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating lease liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:to='lab_us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Earnings Per Share, Basic and Diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule Of Revenues By Product Category</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:to='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net income to net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeMember' xlink:to='lab_us-gaap_ComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Foreign currency translation net of taxes of $0 in all periods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research &amp; development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfGoodsAndServicesSold' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of goods sold</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfGoodsAndServicesSold' xlink:to='lab_us-gaap_CostOfGoodsAndServicesSold'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>OutsideUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the OutsideUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutsideUsMember' xlink:to='lab_fil_OutsideUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareTextBlock' xlink:to='lab_us-gaap_EarningsPerShareTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DividendsCommonStockCash' xlink:to='lab_us-gaap_DividendsCommonStockCash'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsReceivableNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts &amp; other receivables, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsReceivableNetCurrent' xlink:to='lab_us-gaap_AccountsReceivableNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash &amp; investments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash at end of period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>utmd-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20220630"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentQuarterlyReport' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentTransitionReport' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_Security12bTitle' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='33.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='34.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset' xlink:label='us-gaap_OperatingLeaseRightOfUseAsset'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAsset' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_Goodwill' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_Assets' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='25.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='16.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='19.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='19.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='22.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='23.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' use='optional' order='26.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='27.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue_1' use='optional' order='28.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncomeTaxesPaid' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='30.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureBasisOfPresentation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureInventories"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureInventories">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureWarrantyReserve"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserve">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ProductWarrantyDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureRevenueRecognition"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognition">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureEarningsPerShare"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShare">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_EarningsPerShareTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureSubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureSubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ScheduleOfRevenuesByProductCategoryTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensationDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AllocatedShareBasedCompensationExpense' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserveDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProductWarrantyAccrual' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_DomesticUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_OutsideUsMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_ObstetricsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_NeonatalMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20220630.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20220630.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='6.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>utmd-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXK9NDL3JZWVG7APL5A]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2022' xmlns:srt='http://fasb.org/srt/2022' xmlns:fil='http://www.utahmed.com/20220630' xmlns:dei='http://xbrl.sec.gov/dei/2022' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://www.utahmed.com/20220630' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2020-01-21' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
				<link:definition>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
				<link:definition>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShare" id="idr_DisclosureEarningsPerShare">
				<link:definition>000150 - Disclosure - Earnings Per Share</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
				<link:definition>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventories" id="idr_DisclosureInventories">
				<link:definition>000100 - Disclosure - Inventories</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensationDetails" id="idr_DisclosureStockBasedCompensationDetails">
				<link:definition>000220 - Disclosure - Stock-Based Compensation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserve" id="idr_DisclosureWarrantyReserve">
				<link:definition>000120 - Disclosure - Warranty Reserve</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognition" id="idr_DisclosureRevenueRecognition">
				<link:definition>000130 - Disclosure - Revenue Recognition</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" id="idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
				<link:definition>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserveDetails" id="idr_DisclosureWarrantyReserveDetails">
				<link:definition>000230 - Disclosure - Warranty Reserve (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
				<link:definition>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
				<link:definition>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
				<link:definition>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
				<link:definition>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
				<link:definition>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
				<link:definition>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
				<link:definition>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensation" id="idr_DisclosureStockBasedCompensation">
				<link:definition>000110 - Disclosure - Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureBasisOfPresentation" id="idr_DisclosureBasisOfPresentation">
				<link:definition>000080 - Disclosure - Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
				<link:definition>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
				<link:definition>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
				<link:definition>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
				<link:definition>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
				<link:definition>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20220630/role/idr_DisclosureSubsequentEvents" id="idr_DisclosureSubsequentEvents">
				<link:definition>000160 - Disclosure - Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import namespace='http://xbrl.sec.gov/dei/2022' schemaLocation='https://xbrl.sec.gov/dei/2022/dei-2022.xsd'/>
	<import namespace='http://fasb.org/us-gaap/2022' schemaLocation='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd'/>
	<import namespace='http://www.xbrl.org/dtr/type/2020-01-21' schemaLocation='https://www.xbrl.org/dtr/type/2020-01-21/types.xsd'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DomesticUsMember' name='DomesticUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OutsideUsMember' name='OutsideUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ObstetricsMember' name='ObstetricsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NeonatalMember' name='NeonatalMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GynecologyElectrosurgeryUrologyMember' name='GynecologyElectrosurgeryUrologyMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BloodPressureMonitoringAndAccessoriesMember' name='BloodPressureMonitoringAndAccessoriesMember'/>
	<element nillable='true' type='dtr-types:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfRevenuesByProductCategoryTextBlock' name='ScheduleOfRevenuesByProductCategoryTextBlock'/>
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrldt:dimensionItem' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionAxis' name='DistributionRightsAcquisitionAxis'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionDomain' name='DistributionRightsAcquisitionDomain'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CoopersurgicalIncMember' name='CoopersurgicalIncMember'/>
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' name='RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188263836128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000706698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0342734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,624,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188262849696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; investments</a></td>
<td class="nump">$ 66,224<span></span>
</td>
<td class="nump">$ 60,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts &amp; other receivables, net</a></td>
<td class="nump">4,938<span></span>
</td>
<td class="nump">5,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">7,338<span></span>
</td>
<td class="nump">6,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">78,953<span></span>
</td>
<td class="nump">73,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,171<span></span>
</td>
<td class="nump">10,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease - right-of-use assets, net</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,396<span></span>
</td>
<td class="nump">14,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangible assets</a></td>
<td class="nump">52,560<span></span>
</td>
<td class="nump">55,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets - accumulated amortization</a></td>
<td class="num">(39,351)<span></span>
</td>
<td class="num">(38,552)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">13,209<span></span>
</td>
<td class="nump">17,313<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">116,149<span></span>
</td>
<td class="nump">115,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">818<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,621<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,439<span></span>
</td>
<td class="nump">3,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability - Femcare IIA</a></td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">2,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">1,675<span></span>
</td>
<td class="nump">1,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,678<span></span>
</td>
<td class="nump">8,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2022, 3,625 shares and December 31, 2021, 3,655 shares</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(11,858)<span></span>
</td>
<td class="num">(9,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">119,293<span></span>
</td>
<td class="nump">115,314<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">107,471<span></span>
</td>
<td class="nump">107,138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 116,149<span></span>
</td>
<td class="nump">$ 115,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188263737456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="nump">3,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="nump">3,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188264038512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 13,428<span></span>
</td>
<td class="nump">$ 12,604<span></span>
</td>
<td class="nump">$ 25,752<span></span>
</td>
<td class="nump">$ 23,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">5,277<span></span>
</td>
<td class="nump">4,819<span></span>
</td>
<td class="nump">10,069<span></span>
</td>
<td class="nump">8,836<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">8,151<span></span>
</td>
<td class="nump">7,785<span></span>
</td>
<td class="nump">15,683<span></span>
</td>
<td class="nump">14,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,959<span></span>
</td>
<td class="nump">2,892<span></span>
</td>
<td class="nump">5,846<span></span>
</td>
<td class="nump">5,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,094<span></span>
</td>
<td class="nump">3,020<span></span>
</td>
<td class="nump">6,104<span></span>
</td>
<td class="nump">6,080<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">5,057<span></span>
</td>
<td class="nump">4,765<span></span>
</td>
<td class="nump">9,579<span></span>
</td>
<td class="nump">8,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">5,199<span></span>
</td>
<td class="nump">4,825<span></span>
</td>
<td class="nump">9,729<span></span>
</td>
<td class="nump">8,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,103<span></span>
</td>
<td class="nump">$ 3,426<span></span>
</td>
<td class="nump">$ 7,638<span></span>
</td>
<td class="nump">$ 6,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per common share (basic)</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares outstanding - basic</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="nump">3,646<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding - diluted</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">3,655<span></span>
</td>
<td class="nump">3,658<span></span>
</td>
<td class="nump">3,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation net of taxes of $0 in all periods</a></td>
<td class="num">$ (2,298)<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">$ (2,804)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 1,805<span></span>
</td>
<td class="nump">$ 3,475<span></span>
</td>
<td class="nump">$ 4,834<span></span>
</td>
<td class="nump">$ 6,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188262659216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188259508416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="num">$ (8,281)<span></span>
</td>
<td class="nump">$ 110,952<span></span>
</td>
<td class="nump">$ 102,822<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
<td class="num">(1,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,024<span></span>
</td>
<td class="nump">3,024<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="num">(8,335)<span></span>
</td>
<td class="nump">112,937<span></span>
</td>
<td class="nump">104,883<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2021</a></td>
<td class="nump">3,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="num">(8,281)<span></span>
</td>
<td class="nump">110,952<span></span>
</td>
<td class="nump">102,822<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,450<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="num">(8,286)<span></span>
</td>
<td class="nump">115,326<span></span>
</td>
<td class="nump">107,365<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2021</a></td>
<td class="nump">3,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="num">(8,335)<span></span>
</td>
<td class="nump">112,937<span></span>
</td>
<td class="nump">104,883<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2021</a></td>
<td class="nump">3,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(1,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="num">(8,286)<span></span>
</td>
<td class="nump">115,326<span></span>
</td>
<td class="nump">107,365<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2021</a></td>
<td class="nump">3,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="num">(9,054)<span></span>
</td>
<td class="nump">115,314<span></span>
</td>
<td class="nump">107,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(506)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">903<span></span>
</td>
<td class="num">(9,560)<span></span>
</td>
<td class="nump">117,789<span></span>
</td>
<td class="nump">109,168<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2022</a></td>
<td class="nump">3,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="num">(9,054)<span></span>
</td>
<td class="nump">115,314<span></span>
</td>
<td class="nump">107,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,638<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,858)<span></span>
</td>
<td class="nump">119,293<span></span>
</td>
<td class="nump">107,471<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">903<span></span>
</td>
<td class="num">(9,560)<span></span>
</td>
<td class="nump">117,789<span></span>
</td>
<td class="nump">109,168<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2022</a></td>
<td class="nump">3,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(947)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,548)<span></span>
</td>
<td class="num">(2,495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,298)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,051)<span></span>
</td>
<td class="num">(1,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,103<span></span>
</td>
<td class="nump">4,103<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (11,858)<span></span>
</td>
<td class="nump">$ 119,293<span></span>
</td>
<td class="nump">$ 107,471<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188255469008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 7,638<span></span>
</td>
<td class="nump">$ 6,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">3,257<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for (recovery of) losses on accounts receivable</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of Right of Use Assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(286)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit attributable to exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and other receivables</a></td>
<td class="nump">102<span></span>
</td>
<td class="num">(517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(930)<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(357)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">2,240<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">9,878<span></span>
</td>
<td class="nump">10,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(450)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(459)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock - options</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchased and retired</a></td>
<td class="num">(2,495)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(1,060)<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(3,532)<span></span>
</td>
<td class="num">(1,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(637)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="nump">7,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
<td class="nump">60,974<span></span>
</td>
<td class="nump">51,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
<td class="nump">66,224<span></span>
</td>
<td class="nump">59,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">2,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188261900288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2021. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188348183936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(2) Recent Accounting Standards. </p>
 <p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188261350624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">(3) Inventories at June 30, 2022 and December 31, 2021 consisted of the following:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:411.4pt" valign="top"/><td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> June 30, 2022</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2021</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,622</p>
</td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,468</p>
</td></tr>
<tr><td style="width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:31.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:308.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,290</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:288.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,398</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,426</p>
</td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,730</p>
</td></tr>
<tr><td style="width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,338</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,596</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188351227712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(4) Stock-Based Compensation. At June 30, 2022, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, Compensation - Stock Compensation. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended June 30, 2022 and 2021, the Company recognized $40 and $41, respectively, in stock based compensation cost. &#160;In the six months ended June 30, 2022 and 2021, the Company recognized $83 and $82, respectively, in stock based compensation cost.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188263748000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Warranty Reserve</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> (5) Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2021 or June 30, 2022. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI https://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188348183936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(6) Global 2Q 2022 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,006</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">200</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,206</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,394</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,029</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,423</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,514</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">399</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,913</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,915</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,971</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,886</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,829</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,599</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">13,428</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 1H 2022 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,929</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">326</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,255</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,975</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,550</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,525</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,096</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">690</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,786</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,813</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,373</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,186</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">15,813</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,939</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">25,752</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188348238032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">CSI Distribution Agreement Purchase Disclosure</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie&#174; Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;A expenses over a remaining 1.33 year life as of June 30, 2022 of the prior CSI distribution agreement with Femcare.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188261974048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2022.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><i>(in thousands)</i></p>
</td><td colspan="3" style="width:349pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:349.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:349pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:349.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"/><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2021</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2021</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,103</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,426</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,638</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,450</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,643</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,646</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,649</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,645</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">11</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,650</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,655</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,658</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,656</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.13</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.94</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.09</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.77</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.12</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.94</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.09</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.76</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188261462064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188261380208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188260592592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:411.4pt" valign="top"/><td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> June 30, 2022</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2021</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,622</p>
</td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,468</p>
</td></tr>
<tr><td style="width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:31.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:308.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,290</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:288.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,398</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,426</p>
</td><td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,730</p>
</td></tr>
<tr><td style="width:411.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,338</p>
</td><td style="width:24.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,596</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188260597616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock', window );">Schedule Of Revenues By Product Category</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,006</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">200</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,206</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,394</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,029</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,423</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,514</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">399</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,913</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,915</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,971</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,886</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,829</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,599</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">13,428</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 1H 2022 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,929</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">326</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,255</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,975</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,550</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,525</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,096</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">690</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,786</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,813</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,373</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,186</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">15,813</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,939</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">25,752</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfRevenuesByProductCategoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188261244752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><i>(in thousands)</i></p>
</td><td colspan="3" style="width:349pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:349.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Six months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:349pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:349.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">June 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"/><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2021</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2021</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,103</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,426</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,638</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,450</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,643</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,646</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,649</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,645</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">11</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,650</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,655</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,658</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,656</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.13</p>
</td><td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.94</p>
</td><td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.09</p>
</td><td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.77</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:374.95pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.12</p>
</td><td style="width:20pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.94</p>
</td><td style="width:22.7pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.5pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.09</p>
</td><td style="width:19.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:164.75pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.76</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188263769600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 1,622<span></span>
</td>
<td class="nump">$ 1,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="nump">3,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 7,338<span></span>
</td>
<td class="nump">$ 6,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188257845024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188260568240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warranty Reserve (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Standard and Extended Product Warranty Accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188259382512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 13,428<span></span>
</td>
<td class="nump">$ 12,604<span></span>
</td>
<td class="nump">$ 25,752<span></span>
</td>
<td class="nump">$ 23,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_ObstetricsMember', window );">Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember', window );">Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_NeonatalMember', window );">Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember', window );">Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">4,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">7,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">3,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 1,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_ObstetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_ObstetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_NeonatalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_NeonatalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_DomesticUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_DomesticUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_OutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_OutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188261667856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure (Details) - CooperSurgical Inc<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-Lived Intangible Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem', window );">Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System</a></td>
<td class="nump">1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140188264096256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,103<span></span>
</td>
<td class="nump">$ 3,534<span></span>
</td>
<td class="nump">$ 3,426<span></span>
</td>
<td class="nump">$ 3,024<span></span>
</td>
<td class="nump">$ 7,638<span></span>
</td>
<td class="nump">$ 6,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of stock options</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,658<span></span>
</td>
<td class="nump">3,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>utmd-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:fil="http://www.utahmed.com/20220630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20220630.xsd" xlink:type="simple"/>
    <context id="D220101_220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="E22Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="E21Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="I220811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="E21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Y22Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y21Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="D210101_210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="E20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Y22Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Y22Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Y22Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Y22Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Y22Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="E22Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="E22Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="E22Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="E22Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="E22Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Y22Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="E22Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="E22Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="E22Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="E22Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="E20_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="E20_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="E20_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="E20_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Y21Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Y21Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Y21Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Y21Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Y21Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="E21Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="E21Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="E21Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="E21Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="E21Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Y21Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Y21Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Y21Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Y21Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="E21Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="E21Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="E21Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="E21Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="D220101_220630_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y22Q2_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D220630_DistributionRightsAcquisition-CoopersurgicalInc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="UsdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="D220101_220630" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="D220101_220630" id="fact2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="D220101_220630" id="fact3">Yes</dei:EntityCurrentReportingStatus>
    <dei:AmendmentFlag contextRef="D220101_220630" id="fact4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="D220101_220630" id="fact5">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="D220101_220630" id="fact6">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="D220101_220630">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="D220101_220630">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="D220101_220630">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="D220101_220630">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="D220101_220630">001-12575</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="D220101_220630">UTAH MEDICAL PRODUCTS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D220101_220630">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="D220101_220630">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D220101_220630">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D220101_220630">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D220101_220630">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D220101_220630">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D220101_220630">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D220101_220630">566-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="D220101_220630">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="D220101_220630">UTMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="D220101_220630">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityInteractiveDataCurrent contextRef="D220101_220630">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="D220101_220630">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="D220101_220630">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="D220101_220630">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="D220101_220630">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="I220811" decimals="INF" unitRef="Shares">3624932</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E22Q2" decimals="-3" unitRef="USD">66224000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E21" decimals="-3" unitRef="USD">60974000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E22Q2" decimals="-3" unitRef="USD">4938000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E21" decimals="-3" unitRef="USD">5132000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="E22Q2" decimals="-3" unitRef="USD">7338000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E21" decimals="-3" unitRef="USD">6596000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="E22Q2" decimals="-3" unitRef="USD">453000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="E21" decimals="-3" unitRef="USD">456000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E22Q2" decimals="-3" unitRef="USD">78953000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E21" decimals="-3" unitRef="USD">73158000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E22Q2" decimals="-3" unitRef="USD">10171000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E21" decimals="-3" unitRef="USD">10618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="E22Q2" decimals="-3" unitRef="USD">420000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="E21" decimals="-3" unitRef="USD">449000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="E22Q2" decimals="-3" unitRef="USD">13396000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="E21" decimals="-3" unitRef="USD">14098000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E22Q2" decimals="-3" unitRef="USD">52560000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E21" decimals="-3" unitRef="USD">55865000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E22Q2" decimals="-3" unitRef="USD">39351000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E21" decimals="-3" unitRef="USD">38552000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E22Q2" decimals="-3" unitRef="USD">13209000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E21" decimals="-3" unitRef="USD">17313000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets contextRef="E22Q2" decimals="-3" unitRef="USD">116149000</us-gaap:Assets>
    <us-gaap:Assets contextRef="E21" decimals="-3" unitRef="USD">115636000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="E22Q2" decimals="-3" unitRef="USD">818000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="E21" decimals="-3" unitRef="USD">761000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E22Q2" decimals="-3" unitRef="USD">3621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E21" decimals="-3" unitRef="USD">2984000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E22Q2" decimals="-3" unitRef="USD">4439000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E21" decimals="-3" unitRef="USD">3745000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E22Q2" decimals="-3" unitRef="USD">1707000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E21" decimals="-3" unitRef="USD">2105000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E22Q2" decimals="-3" unitRef="USD">1675000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E21" decimals="-3" unitRef="USD">1675000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E22Q2" decimals="-3" unitRef="USD">368000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E21" decimals="-3" unitRef="USD">396000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E22Q2" decimals="-3" unitRef="USD">489000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E21" decimals="-3" unitRef="USD">577000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="E22Q2" decimals="-3" unitRef="USD">8678000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="E21" decimals="-3" unitRef="USD">8498000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="E22Q2" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="E21" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="E22Q2" decimals="-3" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="E21" decimals="-3" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="E22Q2" decimals="-3" unitRef="Shares">3625000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="E22Q2" decimals="-3" unitRef="Shares">3625000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="E21" decimals="-3" unitRef="Shares">3655000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="E21" decimals="-3" unitRef="Shares">3655000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="E22Q2" decimals="-3" unitRef="USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="E21" decimals="-3" unitRef="USD">37000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E22Q2" decimals="-3" unitRef="USD">-11858000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E21" decimals="-3" unitRef="USD">-9054000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E22Q2" decimals="-3" unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E21" decimals="-3" unitRef="USD">841000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E22Q2" decimals="-3" unitRef="USD">119293000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E21" decimals="-3" unitRef="USD">115314000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="E22Q2" decimals="-3" unitRef="USD">107471000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E21" decimals="-3" unitRef="USD">107138000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E22Q2" decimals="-3" unitRef="USD">116149000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E21" decimals="-3" unitRef="USD">115636000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y22Q2" decimals="-3" unitRef="USD">13428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y21Q2" decimals="-3" unitRef="USD">12604000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D220101_220630" decimals="-3" unitRef="USD">25752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D210101_210630" decimals="-3" unitRef="USD">23568000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="Y22Q2" decimals="-3" unitRef="USD">5277000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="Y21Q2" decimals="-3" unitRef="USD">4819000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="D220101_220630" decimals="-3" unitRef="USD">10069000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="D210101_210630" decimals="-3" unitRef="USD">8836000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="Y22Q2" decimals="-3" unitRef="USD">8151000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="Y21Q2" decimals="-3" unitRef="USD">7785000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="D220101_220630" decimals="-3" unitRef="USD">15683000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="D210101_210630" decimals="-3" unitRef="USD">14732000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Y22Q2" decimals="-3" unitRef="USD">2959000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Y21Q2" decimals="-3" unitRef="USD">2892000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D220101_220630" decimals="-3" unitRef="USD">5846000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D210101_210630" decimals="-3" unitRef="USD">5821000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Y22Q2" decimals="-3" unitRef="USD">135000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Y21Q2" decimals="-3" unitRef="USD">128000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D220101_220630" decimals="-3" unitRef="USD">258000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D210101_210630" decimals="-3" unitRef="USD">259000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="Y22Q2" decimals="-3" unitRef="USD">3094000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="Y21Q2" decimals="-3" unitRef="USD">3020000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="D220101_220630" decimals="-3" unitRef="USD">6104000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="D210101_210630" decimals="-3" unitRef="USD">6080000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="Y22Q2" decimals="-3" unitRef="USD">5057000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="Y21Q2" decimals="-3" unitRef="USD">4765000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="D220101_220630" decimals="-3" unitRef="USD">9579000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="D210101_210630" decimals="-3" unitRef="USD">8652000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="Y22Q2" decimals="-3" unitRef="USD">142000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="Y21Q2" decimals="-3" unitRef="USD">60000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="D220101_220630" decimals="-3" unitRef="USD">150000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="D210101_210630" decimals="-3" unitRef="USD">71000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Y22Q2" decimals="-3" unitRef="USD">5199000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Y21Q2" decimals="-3" unitRef="USD">4825000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="D220101_220630" decimals="-3" unitRef="USD">9729000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="D210101_210630" decimals="-3" unitRef="USD">8723000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Y22Q2" decimals="-3" unitRef="USD">1096000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Y21Q2" decimals="-3" unitRef="USD">1399000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="D220101_220630" decimals="-3" unitRef="USD">2091000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="D210101_210630" decimals="-3" unitRef="USD">2273000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="Y22Q2" decimals="-3" unitRef="USD">4103000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y21Q2" decimals="-3" unitRef="USD">3426000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D220101_220630" decimals="-3" unitRef="USD">7638000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D210101_210630" decimals="-3" unitRef="USD">6450000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic contextRef="Y22Q2" decimals="INF" unitRef="UsdPerShare">1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="Y21Q2" decimals="INF" unitRef="UsdPerShare">0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D220101_220630"
      decimals="INF"
      unitRef="UsdPerShare">2.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D210101_210630"
      decimals="INF"
      unitRef="UsdPerShare">1.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="Y22Q2" decimals="INF" unitRef="UsdPerShare">1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="Y21Q2" decimals="INF" unitRef="UsdPerShare">0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D220101_220630"
      decimals="INF"
      unitRef="UsdPerShare">2.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D210101_210630"
      decimals="INF"
      unitRef="UsdPerShare">1.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y22Q2" decimals="-3" unitRef="Shares">3643000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y21Q2" decimals="-3" unitRef="Shares">3646000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D220101_220630" decimals="-3" unitRef="Shares">3649000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D210101_210630" decimals="-3" unitRef="Shares">3645000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y22Q2" decimals="-3" unitRef="Shares">3650000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y21Q2" decimals="-3" unitRef="Shares">3655000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D220101_220630" decimals="-3" unitRef="Shares">3658000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D210101_210630" decimals="-3" unitRef="Shares">3656000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y22Q2" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y21Q2" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="D220101_220630" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="D210101_210630" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y22Q2" decimals="-3" unitRef="USD">-2298000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y21Q2" decimals="-3" unitRef="USD">49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D220101_220630" decimals="-3" unitRef="USD">-2804000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D210101_210630" decimals="-3" unitRef="USD">-5000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Y22Q2" decimals="-3" unitRef="USD">1805000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Y21Q2" decimals="-3" unitRef="USD">3475000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="D220101_220630" decimals="-3" unitRef="USD">4834000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="D210101_210630" decimals="-3" unitRef="USD">6445000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss contextRef="D220101_220630" decimals="-3" unitRef="USD">7638000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D210101_210630" decimals="-3" unitRef="USD">6450000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="D220101_220630" decimals="-3" unitRef="USD">302000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="D210101_210630" decimals="-3" unitRef="USD">325000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="D220101_220630" decimals="-3" unitRef="USD">3257000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="D210101_210630" decimals="-3" unitRef="USD">3335000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="D220101_220630" decimals="-3" unitRef="USD">26000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="D210101_210630" decimals="-3" unitRef="USD">8000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="D220101_220630" decimals="-3" unitRef="USD">26000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="D210101_210630" decimals="-3" unitRef="USD">21000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D220101_220630" decimals="-3" unitRef="USD">-286000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D210101_210630" decimals="-3" unitRef="USD">22000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation contextRef="D220101_220630" decimals="-3" unitRef="USD">83000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="D210101_210630" decimals="-3" unitRef="USD">82000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised contextRef="D220101_220630" decimals="-3" unitRef="USD">0</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised contextRef="D210101_210630" decimals="-3" unitRef="USD">5000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D220101_220630" decimals="-3" unitRef="USD">-102000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D210101_210630" decimals="-3" unitRef="USD">517000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="D220101_220630" decimals="-3" unitRef="USD">930000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="D210101_210630" decimals="-3" unitRef="USD">-75000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D220101_220630" decimals="-3" unitRef="USD">47000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D210101_210630" decimals="-3" unitRef="USD">14000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D220101_220630" decimals="-3" unitRef="USD">64000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D210101_210630" decimals="-3" unitRef="USD">399000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="D220101_220630" decimals="-3" unitRef="USD">-357000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="D210101_210630" decimals="-3" unitRef="USD">34000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="D220101_220630" decimals="-3" unitRef="USD">2240000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="D210101_210630" decimals="-3" unitRef="USD">3775000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D220101_220630" decimals="-3" unitRef="USD">9878000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D210101_210630" decimals="-3" unitRef="USD">10225000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D220101_220630" decimals="-3" unitRef="USD">450000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D210101_210630" decimals="-3" unitRef="USD">222000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="D220101_220630" decimals="-3" unitRef="USD">9000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="D210101_210630" decimals="-3" unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D220101_220630" decimals="-3" unitRef="USD">-459000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D210101_210630" decimals="-3" unitRef="USD">-222000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D220101_220630" decimals="-3" unitRef="USD">23000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D210101_210630" decimals="-3" unitRef="USD">92000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="D220101_220630" decimals="-3" unitRef="USD">2495000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="D210101_210630" decimals="-3" unitRef="USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends contextRef="D220101_220630" decimals="-3" unitRef="USD">1060000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="D210101_210630" decimals="-3" unitRef="USD">2077000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D220101_220630" decimals="-3" unitRef="USD">-3532000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D210101_210630" decimals="-3" unitRef="USD">-1985000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="D220101_220630" decimals="-3" unitRef="USD">-637000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="D210101_210630" decimals="-3" unitRef="USD">-102000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D220101_220630" decimals="-3" unitRef="USD">5250000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D210101_210630" decimals="-3" unitRef="USD">7916000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E21" decimals="-3" unitRef="USD">60974000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E20" decimals="-3" unitRef="USD">51590000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E22Q2" decimals="-3" unitRef="USD">66224000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E21Q2" decimals="-3" unitRef="USD">59506000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesPaid contextRef="D220101_220630" decimals="-3" unitRef="USD">2467000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="D210101_210630" decimals="-3" unitRef="USD">2279000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaid contextRef="D220101_220630" decimals="-3" unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="D210101_210630" decimals="-3" unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:SharesOutstanding
      contextRef="E21_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3655000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-9054000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">115314000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E21" decimals="-3" unitRef="USD">107138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y22Q1" decimals="-3" unitRef="USD">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">43000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y22Q1" decimals="-3" unitRef="USD">43000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-506000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y22Q1" decimals="-3" unitRef="USD">-506000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1060000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y22Q1" decimals="-3" unitRef="USD">1060000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3534000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y22Q1" decimals="-3" unitRef="USD">3534000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3655000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">903000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-9560000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">117789000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E22Q1" decimals="-3" unitRef="USD">109168000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y22Q2" decimals="-3" unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">40000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y22Q2" decimals="-3" unitRef="USD">40000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">30000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y22Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">-947000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y22Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y22Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">-1548000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Y22Q2" decimals="-3" unitRef="USD">-2495000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-2298000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y22Q2" decimals="-3" unitRef="USD">-2298000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1051000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y22Q2" decimals="-3" unitRef="USD">1051000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">4103000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y22Q2" decimals="-3" unitRef="USD">4103000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3625000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-11858000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E22Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">119293000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E22Q2" decimals="-3" unitRef="USD">107471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E20_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3643000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">115000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-8281000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">110952000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E20" decimals="-3" unitRef="USD">102822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y21Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">89000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y21Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y21Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y21Q1" decimals="-3" unitRef="USD">89000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">41000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y21Q1" decimals="-3" unitRef="USD">41000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-54000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y21Q1" decimals="-3" unitRef="USD">-54000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1039000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y21Q1" decimals="-3" unitRef="USD">1039000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y21Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y21Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y21Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3024000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y21Q1" decimals="-3" unitRef="USD">3024000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3646000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">245000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-8335000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">112937000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E21Q1" decimals="-3" unitRef="USD">104883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y21Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y21Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y21Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y21Q2" decimals="-3" unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">41000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y21Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y21Q2" decimals="-3" unitRef="USD">41000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y21Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y21Q2" decimals="-3" unitRef="USD">49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y21Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1037000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y21Q2" decimals="-3" unitRef="USD">1037000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y21Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y21Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y21Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3426000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y21Q2" decimals="-3" unitRef="USD">3426000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3646000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">289000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-8286000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E21Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">115326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E21Q2" decimals="-3" unitRef="USD">107365000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2021. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(2) Recent Accounting Standards. &lt;/p&gt;
 &lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"&gt;(3) Inventories at June 30, 2022 and December 31, 2021 consisted of the following:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:411.4pt" valign="top"/&gt;&lt;td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; June 30, 2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2021&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,622&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,468&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,290&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,398&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,426&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,730&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,338&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,596&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D220101_220630">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:411.4pt" valign="top"/&gt;&lt;td style="width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; June 30, 2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2021&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,622&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,468&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,290&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,398&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:308.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,426&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.45pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:288.6pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,730&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:411.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:308.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,338&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.45pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:288.6pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,596&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E22Q2" decimals="-3" unitRef="USD">1622000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E21" decimals="-3" unitRef="USD">1468000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcess contextRef="E22Q2" decimals="-3" unitRef="USD">1290000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="E21" decimals="-3" unitRef="USD">1398000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials contextRef="E22Q2" decimals="-3" unitRef="USD">4426000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="E21" decimals="-3" unitRef="USD">3730000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet contextRef="E22Q2" decimals="-3" unitRef="USD">7338000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E21" decimals="-3" unitRef="USD">6596000</us-gaap:InventoryNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(4) Stock-Based Compensation. At June 30, 2022, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, Compensation - Stock Compensation. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended June 30, 2022 and 2021, the Company recognized $40 and $41, respectively, in stock based compensation cost. &#160;In the six months ended June 30, 2022 and 2021, the Company recognized $83 and $82, respectively, in stock based compensation cost.&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Y22Q2" decimals="-3" unitRef="USD">40000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Y21Q2" decimals="-3" unitRef="USD">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="D220101_220630" decimals="-3" unitRef="USD">83000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="D210101_210630" decimals="-3" unitRef="USD">82000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0"&gt; (5) Warranty Reserve. &#160;The Company&#x2019;s published warranty is: &#x201c;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#x201d; &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2021 or June 30, 2022. &lt;/p&gt;
</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="E21" decimals="INF" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="E22Q2" decimals="INF" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(6) Global 2Q 2022 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"/&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,006&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;200&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,206&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,394&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,029&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,423&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,514&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;399&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,913&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,915&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,971&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,886&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,829&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,599&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;13,428&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 1H 2022 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"/&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,929&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;326&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,255&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,975&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,550&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,525&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,096&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;690&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,786&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,813&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,373&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,186&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;15,813&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,939&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;25,752&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fil:ScheduleOfRevenuesByProductCategoryTextBlock contextRef="D220101_220630">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"/&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,006&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;200&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,206&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,394&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,029&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,423&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,514&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;399&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,913&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,915&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,971&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,886&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,829&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,599&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;13,428&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 1H 2022 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"/&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,929&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;326&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,255&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,975&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,550&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,525&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,096&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;690&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,786&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,813&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,373&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,186&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;15,813&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,939&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;25,752&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</fil:ScheduleOfRevenuesByProductCategoryTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">1006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-Obstetrics"
      decimals="-3"
      unitRef="USD">1206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">2394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">3029000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      unitRef="USD">5423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">1514000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-Neonatal"
      decimals="-3"
      unitRef="USD">1913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">2915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">1971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      unitRef="USD">4886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">7829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y22Q2_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">5599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y22Q2" decimals="-3" unitRef="USD">13428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">1929000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">326000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-Obstetrics"
      decimals="-3"
      unitRef="USD">2255000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">4975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">5550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      unitRef="USD">10525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">3096000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-Neonatal"
      decimals="-3"
      unitRef="USD">3786000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">5813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">3373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      unitRef="USD">9186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">15813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D220101_220630_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">9939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D220101_220630" decimals="-3" unitRef="USD">25752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie&#xae; Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;amp;A expenses over a remaining 1.33 year life as of June 30, 2022 of the prior CSI distribution agreement with Femcare.&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="-3"
      unitRef="USD">21000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem
      contextRef="D220630_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="INF"
      unitRef="Pure">1.33</fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem>
    <us-gaap:EarningsPerShareTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2022.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:349pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:349.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Six months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:349pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:349.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"/&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2021&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2021&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,103&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,426&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,638&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,450&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,643&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,646&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,649&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,645&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,650&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,655&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,658&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,656&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.13&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.94&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.09&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.77&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.12&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.94&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.09&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.76&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;i&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:349pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:349.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Six months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:349pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:349.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"/&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2021&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2021&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,103&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,426&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,638&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,450&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,643&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,646&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,649&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,645&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,650&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,655&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,658&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,656&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.13&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.94&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.09&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:164.75pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.77&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:374.95pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.12&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:20pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.94&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:22.7pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.5pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.09&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:164.75pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.76&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="Y22Q2" decimals="-3" unitRef="USD">4103000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y21Q2" decimals="-3" unitRef="USD">3426000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D220101_220630" decimals="-3" unitRef="USD">7638000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D210101_210630" decimals="-3" unitRef="USD">6450000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y22Q2" decimals="-3" unitRef="Shares">3643000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y21Q2" decimals="-3" unitRef="Shares">3646000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D220101_220630" decimals="-3" unitRef="Shares">3649000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D210101_210630" decimals="-3" unitRef="Shares">3645000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Y22Q2" decimals="-3" unitRef="Shares">7000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Y21Q2" decimals="-3" unitRef="Shares">9000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D220101_220630" decimals="-3" unitRef="Shares">9000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D210101_210630" decimals="-3" unitRef="Shares">11000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y22Q2" decimals="-3" unitRef="Shares">3650000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y21Q2" decimals="-3" unitRef="Shares">3655000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D220101_220630" decimals="-3" unitRef="Shares">3658000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D210101_210630" decimals="-3" unitRef="Shares">3656000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic contextRef="Y22Q2" decimals="INF" unitRef="UsdPerShare">1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="Y21Q2" decimals="INF" unitRef="UsdPerShare">0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D220101_220630"
      decimals="INF"
      unitRef="UsdPerShare">2.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D210101_210630"
      decimals="INF"
      unitRef="UsdPerShare">1.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="Y22Q2" decimals="INF" unitRef="UsdPerShare">1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="Y21Q2" decimals="INF" unitRef="UsdPerShare">0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D220101_220630"
      decimals="INF"
      unitRef="UsdPerShare">2.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D210101_210630"
      decimals="INF"
      unitRef="UsdPerShare">1.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock contextRef="D220101_220630">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(9) Subsequent Events.&lt;b&gt; &#160;&lt;/b&gt;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +QI#%4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "\:0Q5^VJDP^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O2:5*:'KBV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN
M=W"-#E+W$9]C'S"2Q70SNLXGJ<.:'8F"!$CZB$ZE,B=\;N[[Z!3E9SQ 4/I#
M'1!$5:W (2FC2,$$+,)"9&UCM-01%?7QC#=ZP8?/V,TPHP$[=.@I 2\YL'::
M&$YCU\ 5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.=1S+N_ X>WI\65>M[ ^
MD?(:\Z]D)9T"KMEE\FO]L-EM62LJ(8KJON!BQ^\DK^7MZGUR_>%W%7:]L7O[
MCXTO@FT#O^ZB_0)02P,$%     @ O&D,59E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M!2P%D56>4_'K'#*^FQA#8S]QPS:ITA.F/R[I!B)0M^528&1V+@G+H9",%T3
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M('0"WE]SKO:!WCJ[D]+_ U!+ P04    " "\:0Q5P1&*Y?0%  !U&@  &
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MT24K2H!Z_\RY?+LI&]A_:9K\"U!+ P04    " "\:0Q5V(L5D[T"  #W!P
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M5]Z/Y2(KSWOSJEI]& S*Z9POD_)]ON)9_9_'O%@F5?VV>!J4JX(GLTVAY6*
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MWX'2$W/IR]DL;89RLO!NDG36K]LR259IE2P K\C:DOHHGC>'US/WKK)ION2
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M^X$!&1\]!ZB+J%&96]#Y\7.G$.K4C;ERD_M2L&I@9M4W;#MLG4TC/K!>F(P
M21_CL4H_=B=F=9(C$H08F GQ\"LS@97V)G9)9)?$@*2/_ "IB=AD<B*"! ,S
M"9HW. +[]3J[)+)+8D!"D4H:S*:2,Q ,%1S)4%88#@"&4O<- (T6D"X!]PT
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MQ*G>UHIS3)]WF* #4P3N:"96'(RR!5X<KV])^PHCX=[(S[!6X=^;[ ($WB<
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MI2U*7-U/8,ZB(31HR2+5Z?F1 WG)GD$]>PXU4B'GUF>292I I/,EGQ)J3;W
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MF0'CN4O/Q:H6Z@D1L@T1J 63!M8ESTI@C2V5YK_1ZQ2:20MJ%41 U0YOP"I
MP0N^%-A)&F RAYQK.I9*FQ[<;OA@6:8::0U0MVFUMAPT]&EIN)PMYC +4"X+
MJIHDF<X-Z>1\Q;, /CH\&*5I<CY;7/A1__P]?.R/CK>2@0\AM+_BNBVY2X19
MI 9DJ?O<-^38;(5&U5$1JI NA2V;F3(60I(T>PDH)SU8,:[A@8D&76#/47D
MX5UDNY*Z"EKW#=,6M0%T!VU[6SV%!OWM_>U\YO!NF'C0NR%AJ*0:?5\43\?
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MC_>/[.]][53+DAM\I^H?HK3K:3 *H,05;VN[4-N/N*\G<WR%JHW_A6T7R^(
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M6[R<]FFU1@I)F&00AU<YI&%,D.%B<39Z7'>*3U_'%W#NKD<G%9<6;^_?%3J
MJI=V*+[3Z/1T?1PJ]DOX\.Y]97K/2;3 FE+C<#$/0 ]OR="QJO/U>Z<LO0:^
MV=#SB]H%D+]65-Z.'3?!]*!O_@-02P,$%     @ O&D,56*0+[#W 0  H00
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M3-Y>46+[ ]$':)K8A%N#OJ7CL/9W"-B0X-=WQO^D(0@;C+=2\1M02P,$%
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M+8/+^&*=.7VO\)/CSARLP3&Y5^K!;;Z4RR!R :' PCH$1G^/>(5"." *X_>
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MVHV6)5$P$^PG+70Y\:X\5,"*-$S?B>T7Z/1<6KY<,.6^:-OZCGP/Y8W2HNK
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MG2-=9=[6DAJ:)4JV2+ELJ^8Z?F\\;=TPX?[BQB@[RRQGLF>J%!7F%:U!@SH
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M5G:TFI%F"S8A"=TTTC2P7U*W5;O=?:;@)F@ 9['33J7]\6L(A1A<3RFW+TT
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MJ=NK=K9UF><CK)O+6\6SP[>-PW>9ZU]02P,$%     @ O&D,5?_DO>-" 0
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MW=NU,%+9@S_K?I#,/@%02P$"% ,4    " "\:0Q5!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +QI
M#%7[:J3#[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( +QI#%697)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ O&D,56M&V7C/
M!0  SAX  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( +QI#%6P/GX@]@4   D8   8              "
M@1,.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "\:0Q5
M<CY2XJ("   U!P  &               @($_%   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ O&D,5<$1BN7T!0  =1H  !@
M     ("!%Q<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M +QI#%78BQ63O0(  /<'   8              " @4$=  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " "\:0Q5;E>WD*4)  "A3P  &
M            @($T(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ O&D,57PC0)'4!@  81P  !@              ("!#RH  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( +QI#%52;*P2= ,  (,'
M   8              " @1DQ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " "\:0Q5%V*/(I "  #4!0  &               @('#-
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ O&D,59=N;^YC
M @  1@4  !D              ("!B3<  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " "\:0Q5P3I@+PH#  !J!P  &0
M@($C.@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +QI
M#%6W9/60RP,  #H(   9              " @60]  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ O&D,57,_BT'U @  P 8  !D
M         ("!9D$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " "\:0Q5LP,S=_4"  !P!@  &0              @(&21   >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +QI#%6AF(O\6P,  -P'
M   9              " @;Y'  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ O&D,56*0+[#W 0  H00  !D              ("!4$L
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "\:0Q5HBY(
M59("  #+!0  &0              @(%^30  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( +QI#%6_R1919@(  % %   9
M  " @4=0  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MO&D,546'6.(0 P  W08  !D              ("!Y%(  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " "\:0Q52E>;U  #  #D!@  &0
M            @($K5@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( +QI#%5+;JY:@@(  ,(&   9              " @6)9  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ O&D,51)#4"^& @
MNP<  !D              ("!&UP  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " "\:0Q53)5('!,"  #J!   &0              @('8
M7@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +QI#%48
MR8R0U04  ,@M   9              " @2)A  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ O&D,54FG-/.H @  !@8  !D
M     ("!+F<  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M" "\:0Q5T'!$A>4#  "$$0  &0              @($-:@  >&PO=V]R:W-H
M965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( +QI#%4\&U7!! ,  "T0   -
M              "  2EN  !X;"]S='EL97,N>&UL4$L! A0#%     @ O&D,
M59>*NQS     $P(   L              ( !6'$  %]R96QS+RYR96QS4$L!
M A0#%     @ O&D,5>:J=QSH @  &Q(   \              ( !07(  'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +QI#%7_Y+WC0@$  $40   :
M          "  59U  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( +QI#%6J'1"P=@$  "@1   3              "  =!V  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     B "( )0D  '=X      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>83</ContextCount>
  <ElementCount>131</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserve</Role>
      <ShortName>Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - Warranty Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserveDetails</Role>
      <ShortName>Warranty Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserve</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="utmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="utmd-20220630.htm">utmd-20220630.htm</File>
    <File>utmd-20220630.xsd</File>
    <File>utmd-20220630_cal.xml</File>
    <File>utmd-20220630_def.xml</File>
    <File>utmd-20220630_lab.xml</File>
    <File>utmd-20220630_pre.xml</File>
    <File>utmd_ex31z1.htm</File>
    <File>utmd_ex31z2.htm</File>
    <File>utmd_ex32z1.htm</File>
    <File>utmd_ex32z2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="431">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>43
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "utmd-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 3,
   "contextCount": 83,
   "dts": {
    "calculationLink": {
     "local": [
      "utmd-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "utmd-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "utmd-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 175,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 6
   },
   "keyCustom": 2,
   "keyStandard": 129,
   "memberCustom": 7,
   "memberStandard": 4,
   "nsprefix": "fil",
   "nsuri": "http://www.utahmed.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010 - Document - Document and Entity Information",
     "role": "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000100 - Disclosure - Inventories",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000110 - Disclosure - Stock-Based Compensation",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000120 - Disclosure - Warranty Reserve",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserve",
     "shortName": "Warranty Reserve",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000130 - Disclosure - Revenue Recognition",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure",
     "shortName": "CSI Distribution Agreement Purchase Disclosure",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000150 - Disclosure - Earnings Per Share",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000160 - Disclosure - Subsequent Events",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables",
     "shortName": "Inventories: Schedule of Inventory, Current (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "E22Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "role": "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "E22Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "E22Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
     "shortName": "Inventories: Schedule of Inventory, Current (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "E22Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000220 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "E22Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000230 - Disclosure - Warranty Reserve (Details)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserveDetails",
     "shortName": "Warranty Reserve (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "E22Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2_ProductOrService-Obstetrics",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
     "shortName": "CSI Distribution Agreement Purchase Disclosure (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "E22Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "UsdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "role": "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "E22Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "UsdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "role": "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "role": "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y22Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "E20_StEqComps-CommonStock",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "role": "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "Y21Q1_StEqComps-CommonStock",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "role": "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000080 - Disclosure - Basis of Presentation",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles",
     "role": "http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20220630.htm",
      "contextRef": "D220101_220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 11,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Voluntary filer"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fil_BloodPressureMonitoringAndAccessoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.",
        "label": "Blood Pressure Monitoring and Accessories"
       }
      }
     },
     "localname": "BloodPressureMonitoringAndAccessoriesMember",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.",
        "label": "Common stock received and retired upon exercise of stock options"
       }
      }
     },
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.",
        "label": "Common stock received and retired upon exercise of stock options, shares"
       }
      }
     },
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fil_CoopersurgicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the CooperSurgical Inc, during the indicated time period.",
        "label": "CooperSurgical Inc"
       }
      }
     },
     "localname": "CoopersurgicalIncMember",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_DistributionRightsAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the description of Distribution Rights Acquisition, during the indicated time period.",
        "label": "Distribution Rights Acquisition [Axis]"
       }
      }
     },
     "localname": "DistributionRightsAcquisitionAxis",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fil_DistributionRightsAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Distribution Rights Acquisition, during the indicated time period.",
        "label": "Distribution Rights Acquisition"
       }
      }
     },
     "localname": "DistributionRightsAcquisitionDomain",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_DomesticUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the DomesticUsMember, during the indicated time period.",
        "label": "DomesticUsMember"
       }
      }
     },
     "localname": "DomesticUsMember",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_GynecologyElectrosurgeryUrologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.",
        "label": "Gynecology/Electrosurgery/Urology"
       }
      }
     },
     "localname": "GynecologyElectrosurgeryUrologyMember",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_NeonatalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Neonatal, during the indicated time period.",
        "label": "Neonatal"
       }
      }
     },
     "localname": "NeonatalMember",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_ObstetricsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Obstetrics, during the indicated time period.",
        "label": "Obstetrics"
       }
      }
     },
     "localname": "ObstetricsMember",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_OutsideUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the OutsideUsMember, during the indicated time period.",
        "label": "OutsideUsMember"
       }
      }
     },
     "localname": "OutsideUsMember",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.",
        "label": "Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System"
       }
      }
     },
     "localname": "RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "fil_ScheduleOfRevenuesByProductCategoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.",
        "label": "Schedule Of Revenues By Product Category"
       }
      }
     },
     "localname": "ScheduleOfRevenuesByProductCategoryTextBlock",
     "nsuri": "http://www.utahmed.com/20220630",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r118",
      "r147",
      "r148",
      "r166",
      "r167",
      "r243",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r118",
      "r147",
      "r148",
      "r166",
      "r167",
      "r243",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r166",
      "r168",
      "r268",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r166",
      "r168",
      "r268",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r239"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts &amp; other receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r176",
      "r177",
      "r178",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Total adjustments",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r62",
      "r139",
      "r143"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization {1}",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r13",
      "r68",
      "r107",
      "r110",
      "r116",
      "r127",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r200",
      "r204",
      "r217",
      "r237",
      "r239",
      "r250",
      "r258"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r29",
      "r68",
      "r127",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r200",
      "r204",
      "r217",
      "r237",
      "r239"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r5",
      "r10",
      "r64"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash &amp; investments",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r58",
      "r222"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Net increase in cash and cash equivalents",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r71",
      "r72",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r239"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2022, 3,625 shares and December 31, 2021, 3,655 shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r42",
      "r47",
      "r254",
      "r262"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Total comprehensive income",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r51",
      "r243"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r62",
      "r69",
      "r186",
      "r193",
      "r194",
      "r195"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred income taxes {1}",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r181",
      "r182"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.",
        "label": "Tax benefit attributable to exercise of stock options"
       }
      }
     },
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred tax liability - Femcare IIA"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r62",
      "r145"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r173",
      "r174",
      "r175",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Common stock dividends",
        "negatedLabel": "Common stock dividends"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r48",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r100",
      "r101",
      "r212",
      "r213",
      "r255",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings per share, basic",
        "verboseLabel": "Earnings per common share (basic)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r48",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r93",
      "r94",
      "r95",
      "r96",
      "r100",
      "r101",
      "r212",
      "r213",
      "r255",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings per share, diluted",
        "verboseLabel": "Earnings per common share (diluted)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r43",
      "r44",
      "r45",
      "r71",
      "r72",
      "r73",
      "r77",
      "r85",
      "r87",
      "r103",
      "r128",
      "r163",
      "r164",
      "r176",
      "r177",
      "r178",
      "r187",
      "r188",
      "r211",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r235",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r12",
      "r142"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Other intangible assets - accumulated amortization",
        "negatedLabel": "Other intangible assets - accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r142",
      "r247"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Other intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r11",
      "r134",
      "r135",
      "r136",
      "r137",
      "r239",
      "r249"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r50",
      "r68",
      "r107",
      "r109",
      "r112",
      "r115",
      "r117",
      "r127",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r217"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r46",
      "r107",
      "r109",
      "r112",
      "r115",
      "r117",
      "r248",
      "r253",
      "r256",
      "r264"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income before provision for income taxes",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r70",
      "r86",
      "r87",
      "r106",
      "r183",
      "r192",
      "r196",
      "r265"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r59",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Cash paid during the period for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts payable {1}",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Accounts receivable and other receivables",
        "negatedLabel": "Accounts receivable and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued expenses {1}",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Inventories {1}",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "CSI Distribution Agreement Purchase Disclosure"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r138",
      "r141"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Other intangible assets, net",
        "totalLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventories {2}",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r21",
      "r132"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r6",
      "r27",
      "r239"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r68",
      "r111",
      "r127",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r201",
      "r204",
      "r205",
      "r217",
      "r237",
      "r238"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r68",
      "r127",
      "r217",
      "r239",
      "r251",
      "r260"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r33",
      "r68",
      "r127",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r201",
      "r204",
      "r205",
      "r217",
      "r237",
      "r238",
      "r239"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net cash used in financing activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r58",
      "r60",
      "r63"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r2",
      "r74",
      "r75",
      "r78",
      "r79",
      "r88",
      "r89",
      "r90",
      "r125",
      "r126",
      "r129",
      "r130",
      "r189",
      "r190",
      "r191",
      "r210",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r230",
      "r231",
      "r234",
      "r236",
      "r244",
      "r245",
      "r246",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "New Accounting Pronouncements and Changes in Accounting Principles"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Total operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r107",
      "r109",
      "r112",
      "r115",
      "r117"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating income",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease - right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of Right of Use Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r4",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r28",
      "r239"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r36",
      "r37",
      "r221",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other long term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Common stock purchased and retired {1}",
        "negatedLabel": "Common stock purchased and retired"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payment of dividends",
        "negatedLabel": "Payment of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Intangible assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Property and equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock - options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrual": {
     "auth_ref": [
      "r149",
      "r150",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.",
        "label": "Standard and Extended Product Warranty Accrual"
       }
      }
     },
     "localname": "ProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.",
        "label": "Warranty Reserve"
       }
      }
     },
     "localname": "ProductWarrantyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureWarrantyReserve"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r3",
      "r38",
      "r40",
      "r45",
      "r57",
      "r68",
      "r76",
      "r86",
      "r87",
      "r107",
      "r109",
      "r112",
      "r115",
      "r117",
      "r127",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r199",
      "r202",
      "r203",
      "r207",
      "r208",
      "r213",
      "r217",
      "r256"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r146",
      "r239",
      "r257",
      "r261"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r49",
      "r131"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for (recovery of) losses on accounts receivable"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r180",
      "r242",
      "r287"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research &amp; development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r164",
      "r239",
      "r259",
      "r272",
      "r276"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r71",
      "r72",
      "r73",
      "r77",
      "r85",
      "r87",
      "r128",
      "r176",
      "r177",
      "r178",
      "r187",
      "r188",
      "r211",
      "r269",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r104",
      "r105",
      "r108",
      "r113",
      "r114",
      "r118",
      "r119",
      "r121",
      "r165",
      "r166",
      "r243"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Sales, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r24",
      "r25",
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Equity Balance, shares",
        "periodEndLabel": "Equity Balance, shares",
        "periodStartLabel": "Equity Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r35",
      "r43",
      "r44",
      "r45",
      "r71",
      "r72",
      "r73",
      "r77",
      "r85",
      "r87",
      "r103",
      "r128",
      "r163",
      "r164",
      "r176",
      "r177",
      "r178",
      "r187",
      "r188",
      "r211",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r235",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r103",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20220630/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r163",
      "r164",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Common stock issued upon exercise of employee stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r163",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Common stock issued upon exercise of employee stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock option compensation expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r14",
      "r15",
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Common stock purchased and retired, shares",
        "negatedLabel": "Common stock purchased and retired, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r14",
      "r15",
      "r163",
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Common stock purchased and retired"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r18",
      "r19",
      "r68",
      "r124",
      "r127",
      "r217",
      "r239"
     ],
     "calculation": {
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Total stockholders' equity",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r44",
      "r68",
      "r71",
      "r72",
      "r73",
      "r77",
      "r85",
      "r127",
      "r128",
      "r164",
      "r176",
      "r177",
      "r178",
      "r187",
      "r188",
      "r197",
      "r198",
      "r206",
      "r211",
      "r217",
      "r223",
      "r224",
      "r229",
      "r235",
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Equity Balance, value",
        "periodEndLabel": "Equity Balance, value",
        "periodStartLabel": "Equity Balance, value"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tables/Schedules"
       }
      }
     },
     "localname": "TableTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Dilutive effect of stock options"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r92",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted shares",
        "verboseLabel": "Shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r91",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average shares, basic",
        "verboseLabel": "Shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.utahmed.com/20220630/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20220630/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "https://asc.fasb.org/topic&trid=2155896"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r288": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r289": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r291": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r292": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r293": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r294": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r295": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>44
<FILENAME>0001811884-22-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001811884-22-000012-xbrl.zip
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M?0$8@V_8=5!/J;, ?N14DAN;J837[-PHZ,;=UQF=]MY-WDZ);#=-0.QP(CV
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MS,D=(?V<LR;$F-A\^^ ^\F*D+G55RYJ@0>,FH'CLF'$3NA\(+&)-%GS4G+R
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MK]0%%.31[>:9BGR/;S[BWM2E:M8 (+%S%B&H&HEU+W!/@("]KNI]8\30;(_
MQTZM,,A;3H>O9M9BB^V,8[E^C![WH= PDIKOVJ(');ZV7ATWV]:TWJDX,#4&
M"?!#3'DL,-].6Q&+3.,H-GQ=*L=VB"MM0F?O%[R&(=8JFJYM]'\,#0UV+^P<
MQF>]964T1PF8.%D[O^FN,1H96#\(/$ARY*<-74WYU9QA'ZAY;_+Y+@KO9?K
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M+FT*PA)^&/KRS!&G\!!7L!4^O:F*/?3-LBNY#*\NX)^SRYW!ZC.<*7IV771
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M_&V9,L*+[Q9M+QS2\'TR32 >*Z3ID&0R(TTFB%];")OO.MQN5PE9(DEU,1#
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MU1"J"6L\+Q4NX"T?K@J<C,>:RIRR%OL-7OB1&Q@3DYP70>>[H@$O1,WD N1
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M[8P\SEFLCS(9]I5B,7V3%Q/N_6OMEXT0Z,82-V9>ORUPT!L0>$05OCD6JZ:
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M!SY3VP$;= M>[$B3Z57ZW 2['8[@AAU8-YWP-L\[G(!-77&7SS5R OS$%<G
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ME+8$W^K%8!8O,I[Y(52,$CA!M& H;VG$(I]D[+,%+\1-P_LYX(%1"X]-.%C
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M9X,C+EOW_].YR<D-T$K@8HS@T@&H.._)_JNG4P?<]NVJC0J7S\WD,G,*)&J
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M^M;UG@.'6%B^T;ENT0WL;L%GV4X,L&\[ZX"*-4#W *FNW:=KS^&\OMT>/H8
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MI4>]P!G]#'E534/"V?\:7^",&FG]'WH"UT'#&3T#/_B7W]',.4/3AV"JG=_
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M.,W2EG4=1!.AVOEZ86C)<:T@M<8"7YYX"8T;YYG9S)?:!R?"NO-2*Q(W\-$
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MYEGKWDHK?<W-,(V#ZH8XK7:W6]J00>'[V.M8W#OEZ H9Z+).AM%HM8?#M<C
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MDCYQ;XA/]48_X4:. RK83 ">['2YG=-SJ!+F0Y.*8K/*OVYY.C*N%T>7G46
MFOU]=J- SY)L,9#QB+B#[S*_PF([=VE;X45""S9,=M4.A7P"CAI[:1R!)WX/
M,NB;X&SYI1?J#VG]5>P]^W?P$B=K6IQ,:27W\5JI[HBOSCY_L2XOK5/KTY>_
M7WRV+O]X]^GSQ[,OEY_^V)#Z[#Y'?3HMZX.X 9X@O2G0(=FGXJ1>+T4TCA0B
MX0K@_>V-NH"84&S%H_L]--+&B'.$&LUHC4"BB.MA5M]0VKJ!B(0"6E#$0<8C
MX/M7'\\48!/Y7>_>GJ&RP('+Y;'/SKQ0I]E[UFF>M<CWM=YQ4&C7)UF2#)+[
M7?H_*E$WZT,(9U4:QT4D%G.9X5_93(=;5?8!IZUBH$N&C#"1!I,%[S60/<>]
M9#@,-76>RL#M%9;/7=HJ8EJ[5P6B=SDI@#&UK,\<Z88YOL-J4\J,4.59E*[(
MRF[)YU DQN&^)0U6HE_;T%&P*+E9B,_,82"=J%CXKQQF*\)<RBE?/6D5AZ(#
MB,)[.01"?$@-+GE1ASN+"_95<5,<KV#;;Q%"&&82$A+K(_2O? '&L I]!7.U
M'8POCM$\<X-\T-JI*+:J3M<_O'72ZUD*G[6>WD]N1TWO0"@':<AAKCB1-Z3\
M#Z3TF?#";#91(?JD4A_U-0I0#%YC[#>5:X6U1[ZN$T5A-L=0(R5MW>+].]_:
M+T)O@@WJ9""2[T+.+.:TXB+Y-,DC<Q8I9WQP<RAIL>F<.?-!9-9\CC;XC(LS
MBZN;23R?(]P")5:C_@QN9<VXNCHO;I\^"\P*4BYNI#@;K8,TI4R54#&T6J9A
MHTMSU=.WWK*%E$P;G,L^*_J.00:."K>NM',5U+4])*$]BK0NBX+11-P@]" 6
MJ<I\!3,PN4"UB#1!>T6JD=8<@D%J$[?*-%G8H11LG@"<*[SF  >)JT\9:< N
M4Y.9/2 ?-&(+.O](YN2H$&HQ$9WDPTG9<[XCP(/[DT+#I.\+@OO5>CJOK\H!
M&+0Z10K %U!'J8=),5@#/*>$'EP$\-\2@ZG ,,=_U#XS@"2NQH])E'(_-Y3/
MP&ZP%+\(S?!SI.A@PEP]6OF,3BXAD$).;Y&7>>K@0W7>0@8?X%_"RR<H)2=2
MO@,1T89.\7I"$XKD#B/.BA,VO#7#!,,KB<(ME+984A^$D)RDEW>OP$04;UV9
MQ)CFXWF0RH94(&,"PIE \:C)F.Y!\S%"J*,P4 ("S@74J1!:W<>(BY?Q*L>Q
M?T^7(["U^(Q=-,3#RGN#Q E*CS++4'FQEL&?I93YCT]98R])J%XDID1_E6NF
M$M<XB%&DCJ.-*Y-IB@H=NK4A?F,D#.(G6=2+@Z)HG$N3M2*+"N, CB'&TCUU
MUBE>SDZ"9)+/<7<F0MG-=)1D$A#"2K%W<9Z=QM/313S!RQ7BWY*<B#.6N&4K
MW0*?,%0763[%^.$U1&0G;:^87QOO7(SD!ZCU55N#C$;F?WP318,+5@L(,O5=
MWJ;)IE9(3H'"LB&Y(@DP2%0=!D9\T6)42:'+(&;F>1FY@9P]"IN!9<Q*V!"1
M4V9\ =;84EF*S54"[V$="^NJ0%#[E-R T/A+WJ(<O[_ZQ-BOVEH XYU(7(6D
M;X6BA#OA?1/U 25#?R _(D("\C\8I7S>?%_-)1B:O G:5*IW L%$[)M?E1FS
M\8RNDC3'=5-4*<9,P D;HG(>*?+TC4SY!X6E\#?G;/'/XI1J>121TU4UN2=A
M*),:RAS,5U-*6!>2CZ2JN(E5NBURK:U"9KX@8",ROX4O-Y,<*D3)J1@F*M,
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MSX6.U(?F17')=K8"R >8Q]8!U_0\.A?JFE"<>EMD1!7Q8ZYJ@C:?<3NP+&
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M+S=G]->S>H$/^M3=XMO6%D_ ;NN'._GRH9<;'MC;1NXR/%"V+?H^OPT+J+_
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MD7Y1OGX+ 5P$%8A!MVS;K>FU6+<M$2NO R:U,T1LUFSW-/GSH!15PMI_F[)
M(+MT,P'Z"6?!U/$IJ.$-HJ7MMB=7<DDA6ZK<[I:4*".\&MTU;8QIB*.'*.ZR
M#II2A;Q<(?*OV0E1EH2=+=!A%0+I8 09Z]'C@82I\;*[Q&"_$\+DA)LMRE$5
MHO2) OP$7R+!*!O)7$4,QCLAARG0;"W^7H46SW,FE$"D"R^7)M!SPZUI@#QO
MR0R?0IN9*4>Y=,3O_M[Q?/KVN"3XK*&$3Y;.Z0MZ5:#18ET(M[;GZ]]8>UP$
MI"LEZ !J4HCW,[_A3(<"5 **41>"$D0JHZY6G%=Y/Q;M%798K%'Z<3=&@.G6
M5_I74!V(2>.4W0[(E8ZM1GE%T)FZ4OH$7_A"=R$B*,>_(\\GP7>W 4QY^03E
M/X6A)N_N6\G/#BBW.C<U2DX,Z,/N:$':/$<[JVTN._:RG?3*\)!ZR1*Q3UP"
MF2]N,PRY%Q4$WT..%F.)5E@CA NR;>*IOKIMQ$^V<,=5"Q=V-GOR1?Z^2Q%C
MKK*E_+FR 3:$U_,0X)Y"N6K^J2'3N+Y:+8LR6XA?*A.B3Z:^<,=()OM3:MK.
M4Z>@AQV1K"@?V3J^JZ^.F:/F6BZ^%R7SQ\:3*J2\56,B,A;QKKF45UP0.F(=
M7PC"W-EG@9A$;L ]P\$[+]AUUL;_]:72'-T0=3O\C)X,HF^IL?IWCVVQ;%@9
MV*^B)UW0!XH)PS*1.'20'!OZ@M&\_FJ:(S7H4<E234_P(56ZAQD42!C4G_-D
M- :6XV69]ZV%0,#QUW+W(\%KK+.OY%X;W4.N//Y8PG:DW.9KMANI(-8--H=3
MJ=?>?4'.D:3R=MB#.1B:V6Q7>*[34K:#%T1@@[@;\MAV7>XSI5,9P1F\= .M
M),Q1G3%B(P*Z)FTH<REP*3<G>)/&RQ7"#E(;@G79 [3*!;4A0-)9N81FMVR#
MH&#./M>9NL[*8/RQ-!H8_)9+VU(0-AC\@@3DIFK6AU%'/*R]A]WLL%S.S*W;
M(*M/H"/[\(_+1V$DF_.5X;-<RG(!V&"M(RF\"7\AU?GH2)!@-.U%5?;<<G,V
M5VBK7);7 F:#_7@+28^(8-UB<XY3'LME,J=Y*U.*/Y#DFZ\W@^I9R\+$F_)8
M\C1B;K[BI#+GTA[4%>XL^&LE^2D%Y<ZDJ>N$9#F?U4\XP+Y']+FC\,-9N'06
M[KVRF^\N;:RR?'@%9-M)8.8 HN_D^2PJ\3M0R(\ D"U!-FF\ZI1H':3;F+WG
M.!:_T<L'+MSX%]3S%<&V1-L40+6YP?IH2QON+O167Z^L\2YNK88#7AK:]E8(
MK)&>[[X.ZP7;H76ASK;&I\%OI8L(VV%PK3G&&L\;M;X#DW$,]?_G&+04*@$0
MWLW!P9MYFQ\)'PDT'>O?<C*./>?;UOFX\Y(HJSZ9N4R?L+$D[LRCM/FV%1UO
M+M3!GC4R1[KM$Q)E:%#A<68[,I1[C#E[@R\@(5)1]S[[B%^F216;'PKUFG@G
M;CHH>_T]FT9]"(9BDL/BHD7M24R%M.VS/4O&C"CON!5WD"I2EQBFU$RSNL^F
MV;&9":_%1!KO3X':/H(MC8.XV;;"B32O1RTHDQ5DQ7.H%?HKGD,W4J .T^?M
M0"JB!'5S!OY%DZI&_J4=YGGD3P6U[>GSXXQ!T>GQT0QT<I70Y>B(B-F]"#XT
M<EOLNMH37C!\>Q-PM@HW!!R;GHV285![7A<#LG>&-9O <X]SK+<5ZM643QP(
MX?HL ^!LNP!2!NNR1G97N;KVU*]$Q8^';?QXV,9*#Z<)UB*O@(J.?OP#<M47
MJL8=7RHH_,3E4_3,B+:4T-/T3TZF\S7K>*K_UO^U^,F?XK=U1&"=;5O6EN97
M;[*N.]F^YT5XP[I5@IB^_F]&9-O]YE,9WHWII8%BU]1YG:!@U%571+D0,PO4
MHE=5M%*P4F\K))3]!822I:APU6!;:M1A,:'#.8P2NO;3J[)=YAI+!9-E%;G)
MBCUM_K0,0[!U>GC7CV*@]L7 E::6>/II*UVF$!M1"$MGME$?% 0?&%0K=&G]
MT_UB#&Q[LND3'0Y4%?\D2,C;85!EZ(/[]W?IT>&*BRLR<?7#':X@;QU3TO'H
M]&XF(<:,X<Z>[_JJ:9G#_+7"[9=S:^\/M5;=;8Q@1S;4)N!&LNH_^K__^_#Z
M?U!+ P04    " "\:0Q54X+$P&\F   KWP$ %0   '5T;60M,C R,C V,S!?
M;&%B+GAM;-T]^W/CMID_-W\%+M?I)C/6>KT[VVN>-UH_MFH<R[6\V;:93H8F
M(8D-1:H Z;5R<__[ 2 I42) @/Q "KZ9/"09_%[X  +?\]O_?EI%Z!$3&B;Q
M=R_.7KYZ@7#L)T$8+[Y[$=)D]*<_O?UJ=/;BO[__[-O_&(W0+4F"S,<!>MB@
MRXOWXSN:A2E&-)FGGSR"3] X>/1B/N \6:VS%!,TB>/DT4L9 GK"OO@O3]C?
MUAL2+I8I^N+\2_3ZU:L_C5Z_>OT:_7Q[^[<?OKJYN'[SEW]\_.G]?XUOK]^.
M__D2??KTZ24.%AX1V%[ZR0J-1HRB*(Q__9K_Y\&C&#%68OK=Y\LT77]]>LJ?
M>7H@T<N$+$X9BC>GY<#//_O=[\38KY]HN#?^TYMR]-GIWWZ\GOE+O/)&84Q3
MSI-XCH9?4_'S=>(+I@P0(N4(_FU4#AOQGT9GKT=OSEX^T6!'YCR,]K!DJ;=<
MX8#+X93+[=4?W[S:C>;@VDFA]D0AA[.OOOKJ5/RU,I@!"]+MZ"KLMZ?Y'_<'
MAPVT;"7[_6>_^Y8D$;[#<R00?IUNUOB[SVFX6D?X\^*W)<%S.;2(D%/^_&F,
M4R[&K[@8S_[(Q?B?[*=K[P%'GR,^XL/=1$G05UL8^0.G%LE:>"D.ZJ2)G]N2
M5WEH*!)O,0F3X#+N1NO!T\,2/4L]TEH#Y,\/1?@]VY!Q)Y(K3PY&;))Z43=B
M=T\.1>Q-^\U@_SE!:/[>X=^OV:<]>O%3BN, !R7%'$C##BAPB!V6P2T!)WX5
MY(N(OVD2\J(J@Q=9N@I&Y>8O.&1OB5_82W>5Q+,T\7^]PSX.'W$PCH,[G(8$
M!Q_627SYA(D?4CR=BT'3M7@OSY;LW4U+!(*Q[U[ X9U6>.(P][AB Y*,^/@
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M*TOAK7/0CBE1,^.U\#F]]'L(H[LH(FM%61;1>CQ/1SZ8S\:AD# Z'7[0IEG
M1CO@11*Y(XIB(H!J$)W1#/16<&"VQ%'$DQ:]>"-1#\D@>'$!&4X+)04$6%3
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M%V7Q%:NI'0SHLNI$,61]E0B1EV-$5* Z00\<@\65UAMG#-Y#HEYT139 LL.
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M#&@K\H^<_ZJQP&LTIS?;VC@(>(A7\;_K,,9G2@.;;"S<RM9 @0536P'VI/R
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M4(TVE]>X5T2IB(FT*-PIHE5&^TYT/(MF*3H8WA2?J=VPIJCB:3@CF8U8(R]
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MA.2>\ FB80#1O.,7:NRZ>Q<4.'7B>AM1<_A5=5U8WJ@.*S&[_VYZ'SPR]'O
MZ[\2<XDM3*07:NQ\<BVOP*F;UCMX,H=?53>%Y8WJIA*S^^^F#9;L)$6C2"+\
MMY4UM$ZT-&B57]VHSB?)LC%DA7N"I'7:!I "M'**H'8U_3JR"K(4E_8!@/KW
M;:G5[WM[@9S 1>*H_7AI,[J#TG\0!YVUN\Q?^; >MP%4ZM9USPL?NVLV]\&*
M(R^:5=6=457%NA_=R)&M'.RH%N]Y.[,B79D!D#(R_?N,XJSH7OOX._9^&Z^
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M4\2?H$.0BJ(Y-HJTF%NF ;_ Q< CB2R"  "AD+6\ 3M_?&Z&+(S4V$S1HL5
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M<M%I+,F7=NTYJR9<+XLB$8"%G0@L,UI_%*PUQ\'J4D3%^>N&O/?5+K)0>PS
M4(_ZK=OH_0>VT4NW?:&9MF\PEMCU5OE+=+*.GU4J$P+N419O-4)+TSB:(:,R
MO:Q$]@%4QCB_&V&AMF':2*'.T5@@89M5L N$@9<T\1ZNU(XMTD)\SB5,MRF0
M)[X]L^W]R/TR'6JIDY (,YT1Z+3A2X&X%!5DV;?.!+^DDN JN2T*M@>QKU 6
M!]Q[1;MH,=T);4.V\P 3M5@F^YW(*#H73$&(T6!XKBYI%"6=QW" _%?8S10D
MN_%5P%<1P;6&MO'+=]O.4OD),V26A^ (2P8(KWTO5># <^PMDZF*IH(H/.'C
MXO5:5O"'B--(S05&9Q/E2(-?0QE0\2CUK?STKSO:\,,!:^7C'&Q7JWF,/I\\
MI0$/KS"GO?/A8L((:2*RTD@9H^*#6GK%[/&2/:O:OYVC:R^7[_I?T95;;_2W
MFMBLD#$/^?AP<[D'J.B[<P6 =+J$5,_5.:>M0M^Q<"F^:E7<5[C_ %!+ P04
M    " "\:0Q5ER+$&U,$   A#   #P   '5T;61?97@S,GHQ+FAT;<U7;6_:
M2!#^?K]B3I6:1+*-#4V; $5R@"0T*5 @O?9.]V%MKV%5>]>W7D/X]S>[MA.2
M*&K+Y4Z'(HR]L\^\^'EF-MW+Q<?KWB_=7VT;IE)$14@C"+8P'%SXL[Q@BD(N
M8K4ADEK@1VO"M4%?I%FAJ(01YV)-%!,\M_ F="Q<R[:2+5<*#OM'T'3=$[OI
M-IOPQW3ZY>IT/+AN??C]M\\7[_SI];'_IP.;S<:AT9)(X\T)10JVC1%=#OT!
M7AK5]6PR^(J7P>ASKSL%DK E?U^ZR=4VH>\/8L%5VW,S!0N6TAS&= ,SD1+>
M28E<,MYV#WK=L][P=L4"IJ#5=+QNXZS7;4P1MD8,*==I_1QD?SA;C,Y'?7\Q
MFHQA>C.;W_CC!2PF+X3OG<"-,W?Z#LR'?>/#:QV[U@NA^W/P!Y/I8CCX%T*O
M SYUW\+D'!:70YC[LS-_/)S;DR_7PZ_@]Q=Z!7G2? F?KWF09YT:Y2<VCCB$
M@G,::C+#AJD5J!6%3P61&$*RA1G-A%0@8KA19 4?:<1"DE2B417]X5!O>OWJ
MI-ET.UHEA&_-G=<Y L0]%S(%S[4_02RD<9!1R40$E$>,+^%#P2FT7 NT9"P@
M.<0L0<'=Q3.G82&98I@%X1$,;\,5X4NJ%9FR/->QXY^VC AJ=T4EQ8AWHRKS
MJ(/"L"VXHFO&X=I!%,DW-$E0Q2M&8X1'=XJM*4SBF(7X*A!,8U6I68#/%(OQ
M1U:@@ E7H 3L$+:JIR&L3H=$(E.8T*YY;:1)4N'/B0P(I[D]N4WH%OS0%%Z3
MQ,)UHBR]3QL&-#=+Z1:^<;'!6F$Q=&4"FF &[3V8L">%JA]V0F/5;KW-% K@
MZFQ0 V0B9SK+-@ERD6#S[-Q#]B]*U <0=NN-T]0HA]Y1MX%(/9UOQ<*X2)"2
MV"NS1%/ACAZ2_E4P25/43:[+<E__0X($E. ='T9'=U6^)],=D:I2>Z>M-QU3
MR+T5];^K8W.GCHRC %,SN;3N%6$<6<E*Z=1%)DP+/Y,TU_6T]#))$L!M*%K4
M/BYDU&A?[XH9Q^FHGR-@9((T!42K(C%%%2CV<E@^TI&S;ZT4O54VXQ'&U[;?
MM9R33#U(OGST#]KBWAN[YQ,<)-6&0,B(2CL02HFT[66W>*A(6 2O7/,YZ%4L
M>_K=R!M/V].SUG6TVG=OCZ"?>-H#XYG.N0>27RP+[&Z>5XZ#__+M?6?C(Z$]
M>=_:THY)RI)M^Y$3M!SU?,AQO*/@!![A4#9)J0>&G0S[D:(<@5!DNHW5+<V<
M2G<FA:6[F4 -28A$6!A34N ]5SB7%0Y3G#=A/1/,;;UAPW):#B(]<K4,=31$
M%9*:X0(DRRB>1TT[V&;H6O<*TV2K!D$3#$0*SD)84UE.W6<36.'8"R@^RJ18
MLPCAJME5B=\TB0U#6@>Z@5>M"+-];!,7DK-\=0_P(X<!"0Q' 483QU!D^$37
M$X>FTVV,>@^4TM!G:[Q4)^U&^9_!WU!+ P04    " "\:0Q5]#'563H$   *
M#   #P   '5T;61?97@S,GHR+FAT;<U7:V_;-A3]OE]QAP)- DBR9#==8KL&
MY%?BQK5=V^G:#?M 291-5"(YBHKC?[]+6DZ<!!N6K"L:!-&#Y.&]1_><R[0O
MEQ_&G9_:/[LNS)1(RI@F$&UAT+\(YT7)-(5"I'I#%'4@3&X(-Q-Z(I>EI@I&
MG(L;HIG@A8,/L>?@F-PJMEIK..Z=0-WWS]RZ7Z_#[[/9YZOS27_<>/_;KY\N
M?@EGX]/P#P\VFXU'DQ51=C<O%CFX+D9T.0C[>*E5U^ZT_P4O_=&G3GL&)&,K
M_FZW3:&W&7UWE JNFX$O-2Q93@N8T W,14YX*R=JQ7C3/^J\YE$A6R_[V^YV
M!K=K%C$-C;I7;]>ZG79MAB'MHXDI-Y0\(QR$[ WFR]%PU N7H^D$9M?SQ74X
M6<)R^HWP@S.X]A9>SX/%H&?W"!JGOO.-T,,%A/WI;#GH_P^A[P,^]]_"= C+
MRP$LPGDWG P6[O3S>/ %PM[2C&"-/?@<SRZ(%RP<<8@%YS0VM0\;IM>@UQ0^
MED1AIMD6YE0*I4&D<*W)&C[0A,4DJS2F*[7 L5GT^M59O>ZWC*@(W]JGH'4"
MB#L4*H? =S]"*I3=0%+%1 *4)XROX'W)*31\!XS"'" %I"Q#?=[%LZ!QJ9AF
MF 7A"0QNXS7A*VH$G+.B,+'CKYF9$)3ZFBJ*$1]&M<MC'Q2&[4!7,<)A[,&5
M$!)I<3 KQF,F,;\AXV@1#.^F:<IB_.B(9^"J[!S =YJE>"-+E#SA&K2 @S*M
M*+5E:C(BB9 :<SJ<OI]D2J/"7Q 5$4X+=WJ;T2V$L>7>E(:#XT0[9IV9&-'"
M#N5;^,K%!NE"/@PY$<T839O?KXJJ&S>CJ6XVWDJ-97_5[>\!I"B8R;))HD)D
M:+>M>\C>Q0[U 83;>./5#<IQ<-*N(5+'Y%L58EIF6)7HKC(SU7!7(8K^63)%
M<U1H86BYY_^88 TJ"$Z/DY,[EN_KZ:Z6*JJ#\\:;EB7RQ:+ZX7BL'_#(.&HP
MM[W.2%\3QK$JV4X]>Y(),]J7BA:&3\<,DRP#7(:Z15'@@*16_F95>B<6!$QL
MD)9 G%5FEE2!>M^UUT<Z\KXWR?]A87LXQ;Y0+8B$2JAR(Z&UR)N!O,7S1<82
M>.7;GZ,.'#;=ZJ%6U)ZX3KMF8%]B^D^1G@WQ#X;W K2P7)5H2D&P,_(?Z*,^
MTL>3KVEFNBG)6;9M/MH$9XXZ(138_U$G L]JR%2V*V.&!H0VHBE'(-2&<9^]
M$]GCYX'!.\:$!):^@D3$I9U*2GSF&CNJQC:(;2+>6[E]W"_8L(+N^H=IED8]
M)AJB2T5M3P B)<6#IU7Q5N+61N+6&RM=TPP#48*S&&ZHVO7+OTU@C=TJHOA*
M*G'#$H2K6DZE6:OM#4,_B(SO5@Z"V3Z>DY:*LV)]#_!OVK@"A@Z.T:0IE!+?
M&#ZQUWGMVJCS0"PU<XC&2W6DKNW^!?@+4$L! A0#%     @ O&D,5:&CN>B:
MJ   Z%D( !$              ( !     '5T;60M,C R,C V,S N:'1M4$L!
M A0#%     @ O&D,51W$]$%6"   540  !$              ( !R:@  '5T
M;60M,C R,C V,S N>'-D4$L! A0#%     @ O&D,55P%^NNW"0  DWT  !4
M             ( !3K$  '5T;60M,C R,C V,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( +QI#%7?F 5(HPD  /QQ   5              "  3B[  !U=&UD+3(P
M,C(P-C,P7V1E9BYX;6Q02P$"% ,4    " "\:0Q54X+$P&\F   KWP$ %0
M            @ $.Q0  =71M9"TR,#(R,#8S,%]L86(N>&UL4$L! A0#%
M  @ O&D,52FG(9NU%P  >GX! !4              ( !L.L  '5T;60M,C R
M,C V,S!?<')E+GAM;%!+ 0(4 Q0    ( +QI#%5:(_Q]\@8  )\;   /
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) @  P!H!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
